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ABSTRACT 
 
     β2AR (β2 adrenoceptor) is a prototypical G-protein coupled receptor (GPCR) that plays an 
important role in cardiovascular and pulmonary physiology through activation of the classic Gs-
adenylate cyclase-cyclic adenosine monophosphate (cAMP)-protein kinase A (PKA) signaling 
pathway. In the mammalian heart, increasing cAMP-PKA activity leads to phosphorylation of an 
array of proteins involved in increasing heart contractility and rate. β2AR also has a cardiac 
protective role through utilizing multiple mechanisms to reduce receptor signaling. This includes 
β2AR desensitization, β2AR coupling to Gαi, and β2AR degradation, all of which are tightly 
regulated by post-translational modifications of the C-terminal region of β2AR. Over past 
decades, these modifications have been extensively characterized biochemically in fibroblasts, 
such as phosphorylation by PKA (serines 261, 262, 345, and 346) and G protein coupled receptor 
kinases (GRKs) (serines 355, 356, and 364), ubiquitination (lysines 348, 372 and 375) and 
palmitoylation (cysteine 341). However, the physiological role of these modifications on β2AR 
signaling regulation in the heart remains unclear. 
     This study provides new insight into the role of three post-translational modifications on 
β2AR signaling regulation in cardiac myocytes. We find that palmitoylation, the fatty acid 
modification of β2AR at cysteine 341 is not required for receptor targeting to the plasma 
membrane caveolae. Instead, both palmitoylation and GRK phosphorylation are required to 
mediate the association of β2AR with β-arrestin 2/ phosphodiesterase 4D complexes to regulate 
cAMP signaling. In addition, we provide a new mechanism explaining β2AR coupling from Gas 
to Gai, which is agonist dose-dependent and controlled by both PKA and GRK phosphorylation 
of the receptor. Moreover, we demonstrate that mutation of either PKA or GRK phosphorylation 
sites on β2AR leads to rapid receptor degradation than that of wild type β2AR. Interestingly, our 
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data also suggest that degradation of β2AR is coordinated by both lysosomes and proteasomes: 
the extracellular domains are degraded by lysosomes and the intracellular domains are degraded 
by proteasomes. Together, all three post-translational modifications coordinate to regulate β2AR 
signaling in cardiac tissue under physiological conditions.  
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CHAPTER 1 
Introduction 
1.1 Introduction 
      Transducing extracellular signals to intracellular effectors is mainly mediated by 
transmembrane receptors including G protein-coupled receptors (GPCRs), receptors with 
intrinsic or associated enzymatic activities, ion channels and intracellular receptors. Among them, 
GPCRs comprise the largest family of transmembrane proteins that mediate physiological 
responses to various extracellular stimuli, such as hormones, neurotransmitters and sensory 
stimuli. Because of receptor diversity and signaling complexity, GPCRs are involved in nearly 
all biological functions.  Dysfunctions of GPCRs have been found in many human diseases, such 
as hypertension, heart failure, obesity, cancer, Alzheimer disease, and Parkinson disease (1, 2).   
Currently, ligands acting on GPCRs represent the predominant family of pharmaceutical agents 
on the market (3-5).   
GPCR signaling: ligand binding, G protein activation, second messenger production and 
physiological function  
        GPCRs are evolutionarily conserved from bacteria to mammals and share a common 
membrane topology with an extracellular N terminus, a cytoplasmic C terminus and seven 
transmembrane α helical domains connected by three extracellular loops and three intracellular 
loops. Because some GPCRs use both heterotrimeric G proteins as wells as non-G proteins such 
as arrestins to transduce signaling, they have another popular name: seven transmembrane 
receptors (6). Based on sequence and structure similarity, GPCRs are further classified into five 
families: the secretin receptor family, the adhesion receptor family, the glutamate receptor family, 
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the Frizzled/Taste 2 receptor family, and the rhodopsin receptor family (7-9). The rhodopsin 
receptor family is by far the largest GPCR subfamily (10). 
       In the classical view of GPCR signaling, a ligand binds to a receptor leading to receptor 
activation for interaction with heterotrimeric G proteins. A great deal of effort has been devoted 
to understand the binding sites/pocket of the ligand to the receptor in order to develop specific 
agonists. Instability of GPCRs when not in the plasma membrane and the multiple conformations 
of the extracellular loops make it difficult for GPCR purification. This difficulty hinders the 
study of their crystal structure. Recently, crystal structure studies on a handful of GPCRs show 
that both transmembrane domains and extracellular loops are involved in agonist binding. Loop 2 
has direct binding to the agonist, whereas loop 1 and 3 influence the agonist binding (11-13).  
       Ligand binding triggers GPCR conformation changes of the transmembrane domains, which 
is then propagated to cytoplasmic domains of the receptor involved in G protein activation (14).  
Due to the transient interaction between the receptor and G proteins, it is difficult to detect their 
interaction by conventional biochemical methods. Recently, the fluorescence resonance energy 
transfer (FRET) technique has been developed and widely utilized for the detection of transient 
GPCR-G protein interactions. Two models are presented to explain how G proteins are coupled 
with the receptor: the receptor and G proteins are pre-coupled for constitutive receptor activity 
and agonist binding-dependent receptor-G protein interaction (15-17). Activated GPCRs act as 
guanine nucleotide exchange factors (GEFs) to catalyze the release of GDP and binding of GTP 
to α subunit of G proteins. The Gα subunits encoded by sixteen genes in humans are divided into 
four subfamilies based on sequence similarity: Gαs, Gαi, Gαq, and Gα12. Gα proteins have 
GTPase domains to hydrolyze GTP and provide the binding surface for the βγ complex (18). Gα 
proteins modulate the activity of downstream effectors including adenylate cyclase (AC), 
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RhoGEF, and phospholipase C (PLC). The activity of these effectors generates second 
messengers including cyclic adenosine monophosphate (cAMP), diacylglycerol (DAG) and 
inositol-1,4,5-trisphosphate (Ins(1,4,5)P3) that further regulate downstream signaling 
components such as protein kinase A (PKA) and protein kinase C (8, 19) (Fig. 1.1). For example, 
Gαs activates adenylate cyclases to convert ATP to cAMP. cAMP binds to PKA causing the 
release of catalytic subunits of PKA to phosphorylate a variety of cytosolic proteins to trigger 
specific cellular responses (20, 21). Meanwhile, the released βγ complex also regulates the 
activity of PLC (22) and certain ion channels (23, 24).   
Adrenergic receptors: subtype signaling and physiological function  
     Adrenergic receptors belong to the rhodopsin family of GPCRs that mediate the stress 
responses within the body, including acceleration of heart, brain, and lung function, constriction 
of blood vessels to limit blood supply to nonessential organs, and liberation of fat and glucose 
for muscle use (9). So far, α and β adrenergic families have been characterized. The adrenergic 
receptor family includes α1AR (α1A AR, α1B AR, and α1D AR) and α2 AR (α2A AR, α2B AR, and 
α2C AR).  Molecular cloning and pharmacological identification of α1ARs were performed in the 
late 1980s and early 1990s. α1ARs have been found in multiple tissues including vas deferens, 
colon, stomach, brain, heart, liver, aorta, and adrenal gland (25). α1ARs couple to Gq-PLC 
pathway, eventually resulting in calcium release and smooth muscle contraction (26). α1ARs 
have been implicated in many human diseases such as hypertension, myocardial hypertrophy and 
heart arrhythmias (27). Molecular cloning and pharmacological identification of  α2ARs were 
carried out in the 1990s (28, 29). α2ARs are also expressed ubiquitously including in aorta, heart, 
lung, skeletal muscle, liver, pancreas, kidney, stomach, spleen, and brain tissues (30). α2ARs 
couple to inhibitory G proteins (Gi) to inhibit cAMP production. α2AR subtypes have been 
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implicated in smooth muscle constriction and  reduction of  norepinephrine release from nerve 
terminals (31-33).  
      There have been three β adrenergic receptor subtypes (β1AR, β2AR and β3AR) identified so 
far with different chromosome localizations and a 51% protein sequence homology (34-36). The 
β adrenergic receptors were first identified in a dog’s heart in the 1970s using [3H] 
dihydroalprenolol labeling and later found in other species (9, 37). β adrenergic receptor 
subtypes were defined by relative binding affinity for norepinephrine and epinephrine. β1AR has 
a similar affinity for both agonists, whereas both β2AR and β3AR have a higher affinity for 
epinephrine than for norepinephrine (38, 39). Later, β2AR, β1AR and β3AR genes were 
sequentially cloned from the human cDNA library (34, 35, 40). Interestingly, both β1AR and 
β2AR genes contain no intron while β3AR contains one intron (41-43).  
      In terms of tissue distribution, β1AR is ubiquitously expressed with abundant expression in 
heart and kidney (44). β2AR are found mainly in lungs, gastrointestinal tract, liver, uterus, 
vascular smooth muscle, and skeletal muscle (45). Besides heart function regulation, β1AR and 
β2AR are implicated in lipolysis (46, 47) and kidney function regulation (48-50). β3AR mRNA is 
highly expressed in infant brown adipose tissue and adult white adipose tissue and not detectable 
in muscles, heart, liver, lung, kidney, thyroid and lymphocytes, suggesting the role of β3AR in 
energy metabolism (51).  
     In the heart, circulating norepinephrine and epinephrine activate β adrenergic receptors on the 
plasma membrane to elicit the Gαs-adenylate cyclase-cAMP-PKA signaling pathway. PKA 
phosphorylates many substrates in the cardiomyocytes. This includes the L type calcium 
channels on the plasma membrane and the ryanodine receptor on the sarcoplasmic membrane for 
calcium influx into cytosol. Also the phospholamban for calcium re-uptake back into 
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sarcoplasmic reticulum for myocyte relaxation, and the troponin proteins for myocyte 
contraction are substrates of PKA phosphorylation (52-54).  It has been shown that βAR 
subtypes play a non-redundant role in heart function regulation (55). β1AR has abundant 
expression (70%) and plays a predominant role in increasing heart contractility and frequency. 
β2AR comprises around 30% of total βAR expression in the heart, and stimulation of β2AR 
increases heart contraction rate but to a lesser extent. The function of β3AR in the heart is not 
clear yet although a negative inotropic effect has been reported (56, 57). Currently, β3AR is  
implicated in mediating metabolic effects in adipose tissue and its agonist is a promising  option 
for treatment of obesity patients (58).       
β adrenergic receptor signaling and heart failure  
    Chronic heart failure is one of the leading causes of mortality in developed countries.  It has 
been shown that in heart failure patients, the circulating norepinephrine level is much higher than 
that in normal persons. This indicates that a sustained, high level of norepinephrine may lead to 
cardiac toxicity and heart damage (59). Interestingly, β1AR levels in these patients are greatly 
reduced, whereas β2AR levels are not significantly diminished (60-62).  A 5- 40 fold increase of 
β1AR expression in transgenic mice hearts leads to cardiac hypertrophy, myocyte apoptosis and 
premature death within several months of birth (63). An in vitro study using primary adult 
myocytes showed that stimulation of β1AR leads to myocyte hypertrophy and apoptosis through 
activating calcium-calmodulin dependent protein kinase II pathway as well as a calcium 
independent pathway (64, 65). Stimulation of β2AR has been shown to protect the cells from 
hypoxia and reactive oxygen species (ROS) (66).  Transgenic mice with a 30-fold increase of 
β2AR level have improved cardiac performance, suggesting that β2 adrenergic activation may 
provide a compensatory mechanism to protect the heart (33, 67).  
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β2AR post-translational modifications 
β2AR has been the prototypical GPCR extensively studied for its signaling regulation, 
especially the post-translational modifications within the intracellular loops and C terminus (68) 
(Fig. 1.2). Most of these post-translational modifications have been studied in fibroblasts such as 
HEK293 cells.  Human β2AR has been found glycosylated on asparagines at the N terminal 
residue 6 and 15 and the extracellular loop 2 residue 187. A mutagenesis study reveals that only 
asparagine 187 plays an important role in preventing β2AR from down-regulation in lysosomes 
under sustained agonist stimulation (69). Upon activation by agonist binding, β2AR can be 
phosphorylated by PKA at four serine sites (261, 262, 345 and 346) in an agonist dose-dependent 
manner which is involved in β2AR/Gi coupling to desensitize the receptor (70, 71). β2AR can 
also be phosphorylated by G protein receptor kinases (GRKs) at three serines (355, 356, and 364) 
of the C terminus, which leads to recruitment of β arrestin 2. This recruitment functionally 
diminishes receptor and Gs coupling, thus desensitizing the receptor. In addition, β arrestin 2 also 
serves as an adaptor protein for clathrin-AP2 complex for receptor internalization through 
clathrin-coated pit pathway (72, 73).  
 Besides these modifications, β2AR is also palmitoylated at cysteine 341. Palmitoylation is a 
fatty acid modification by adding a 16-carbon palmitic acid to a cysteine residue catalyzed by a 
group of palmitoyl transferases (PATs). In humans, 22 PATs have been characterized with 
different subcellular localizations (74, 75). It is still unknown which PAT is involved in β2AR 
palmitoylation. β2AR palmitoylation is proposed to help create the “ helix 8 ” of the receptor by 
attachment of the C terminus of the receptor to the plasma membrane. Alanine substitution of 
cysteine 341 leads to increased cAMP/PKA activity at basal conditions (76-79). Moreover, 
ubiquitination plays an important role in targeting β2AR for degradation. Ubiquitination is 
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another type of post-translational modification, in which a 76- amino acid-ubiquitin protein is 
attached to the lysine residue catalyzed by E1 (ubiquitin activating enzyme)-E2 (ubiquitin 
conjugation enzyme)-E3 (ubiquitin ligase) enzymes. Protein ubiquitination is involved in many 
cellular processes such as the cell cycle, protein quality control and host immune defense. Up to 
now, it has been well accepted that the C terminus of β2AR containing three lysine residues (348, 
372 and 375) is the primary region of ubiquitination (80, 81). Recently, two additional lysine 
residues within intracellular loop 3 (lysine 263 and 270) are also found involved in receptor 
ubiquitination (82).  
β2AR trafficking 
     Literature has suggested that β2AR trafficking is tightly regulated by core sequences in the 
receptor as well as intracellular vesicle trafficking sorting proteins. The distal region of β2AR-
DSLL is a substrate of GRK5 whose phosphorylation is important for binding between receptor 
and EBP50 (ezrin-radixin-moesin (ERM)-binding phosphoprotein-50) (83). Loss of EBP50 
binding reduces receptor recycling. A recent study also shows that mutation of PKA 
phosphorylation sites (serines 345 and 346) on β2AR reduces receptor recycling frequency (84). 
Mutation of GRK phosphorylation sites impairs β2AR internalization and potential recycling (70, 
85).  
       Intracellular vesicle sorting proteins also regulate β2AR fate.  After its internalization via the 
clathrin-coated pit pathway (86), β2AR-ligand complex is sorted to peripheral tubulovesicular 
sorting endosomes where ligand is dissociated from the complex due to the acidic pH.  β2AR 
may rapidly recycle back to the cell surface through recycling endosomes, which is mediated by 
Rab4, a GTPase of the Rab families regulating vesicle trafficking (84, 87, 88). β2AR may recycle 
slowly back to the cell surface through recycling endosomes, which is mediated by Rab11 
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GTPase (89, 90) (Fig. 1.3). Studies have shown that these two recycling endosomes are quite 
different (91, 92). Alternatively, β2ARs are sorted to lysosomes or proteasomes for degradation, 
thus terminating receptor signaling (81, 82, 93). Two key proteins have been identified to be 
involved in sorting internalized β2AR from early endosomes to lysosomes: GASP (G protein 
coupled receptor sorting protein) and Hrs (hepatocyte growth factor-regulated tyrosine kinase 
substrate). GASP has been shown bound to the C terminus of several GPCRs. Dominant-
negative inhibition of GASP blocks the lysosome sorting and degradation of the receptors, 
including β2AR (94-96). Hrs is the mammalian homologue of VPS27 (vacuolar protein-sorting) 
protein in the yeast. Hrs associates with endosome membranes and binds to ubiquitinated or non-
ubiquitinated cargoes and sorts them for recycling as well as for degradation in lysosomes (97, 
98).     
The role of lysosomes and proteasomes in β2AR degradation 
     Protein degradation has diversified functions: to remove unstable proteins, to provide energy 
by degrading non-essential proteins under starvation conditions, and to control the level of 
important proteins. Both lysosomes and proteasomes are compartmentalized multi-enzyme 
systems to degrade proteins in an energy dependent manner. It is proposed that proteasomes 
degrade short-lived proteins such as cyclins, p53, c-fos, and c-jun in an ubiquitination-dependent 
manner. And lysosomes non-selectively degrade long-lived proteins with or without 
ubiquitination (99, 100). Besides degrading proteins, lysosomes are also involved in degradation 
of lipids, starch and nucleic acids.  
       Mammalian 26S proteasome is a barrel-shaped protease with a molecular weight of 2.5 MDa 
and composed of one 20S cylindrical core particle and two 19S regulatory caps on both ends 
(101). Studies have demonstrated that the 19S caps contain ubiquitin recognition motifs for 
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identification and transport of ubiquitinated proteins into the narrow pore of the 20S particle 
(102). Once inside the pore, proteins are denatured and degraded into short peptides with various 
lengths by the protease activity of the 20S subunits. In addition, the 26S proteasomes were once 
thought as completely processive proteolytic engines but now it is appreciated that 26S 
proteasomes may only degrade the C terminus of the proteins. Studies reveal that NF-kappaB, 
the master transcriptional regulator in immune response, is activated by proteasome-mediated 
cleavage of its precursor p105 to p50 (103). Recently, two models have been proposed to explain 
the degradation of the C terminus: stop-transfer model and the loop-model. In the stop-transfer 
model, the target protein is degraded from the C terminus until the proteasomes meet the stop 
signal. Then the N terminus is prevented from degradation and released (103). Studies on mouse 
ornithine decarboxylase demonstrate that the glycine-alanine repeat in the C terminus of 
ornithine decarboxylase is important for protein unfolding in the 20S core and may serve as the 
stop signal for degradation in proteasomes (104). In the loop-model, the protein C terminus may 
form a loop and is internally cleaved by the proteasomes and the intact N terminus is released for 
signaling (105). 
       Big protein complexes from phagocytosis, endocytosis, and autophagy are released into 
lysosomes by membrane fusion and then degraded by the proteases in the acidic environment.  
Recently, it is more appreciated that degradation of some proteins is mediated by both lysosomes 
and proteasomes: the C terminus which is ubiquitinated is cleaved by the proteasomes and the 
remaining N terminus is then transferred into the lysosomes for complete degradation (106, 107). 
An interesting hypothesis has been proposed that similar to the degradation of other membrane 
receptors, the extracellular domains of β2AR may be degraded in lysosomes and the intracellular 
domains are degraded in proteasomes (4). Studies have shown that degradation of β2AR is 
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mediated by both lysosomes and proteasomes in an ubiquitination dependent manner. Mutation 
of all three primary ubiquitination sites on the C terminus reduces receptor degradation in 
lysosomes (81). However, there is no report on the differential degradation of extracellular and 
intracellular domains by lysosomes and proteasomes. 
1.2 Aims 
      Although the function of post-translational modifications of β2AR has been extensively 
studied in heterogeneous cell culture systems such as fibroblasts, their function in regulating 
β2AR signaling in the heart is not clear. In the current study, we reveal the effect of three post-
translational modifications on β2AR signaling regulation in the heart: palmitoylation, PKA and 
GRK phosphorylation. 
1) β2AR palmitoylation 
      A series of excellent studies have previously characterized cysteine 341 as the palmitoylation 
site on the human β2AR.  Mutation of the palmitoylation site on the β2AR leads to increased 
cAMP and PKA activity induced by the receptor. However, the molecular mechanism underlying 
the altered cAMP-PKA activity is not yet clear. In our current study, we focus on three 
fundamental questions regarding β2AR palmitoylation: 
a) Is β2AR palmitoylation required for plasma membrane localization? 
b) Is β2AR palmitoylation required for association with downstream effectors? 
c) What’s the functional role of β2AR palmitoylation in the heart? 
      We demonstrate that palmitoylation, the fatty acid modification of β2AR at cysteine 341 is 
not required for receptor targeting to the plasma membrane caveolae. Instead, together with GRK 
phosphorylation, they mediate the association of β arrestin 2/phosphodiesterase 4D complexes 
with β2AR to regulate receptor signaling. Loss of PDE4D recruitment to palmitoylation-deficient 
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β2AR results in a stronger contraction rate response to the stimulation of the receptor in 
myocytes.   
2) β2AR- Gi coupling  
     Previous studies of β2AR coupling to Gi have been mainly conducted by using the in vitro 
reconstitution system, which lacks the physiological circumstances of this coupling. In addition 
to the PKA phosphorylation-dependent β2AR/Gi coupling, GRK phosphorylation is also 
implicated for β2AR/Gi coupling (108). Furthermore, PKA phosphorylation of β2AR occurs by a 
wide range of agonist concentrations, whereas GRK phosphorylation only happens at high 
agonist concentration (109). We hypothesize that both PKA and GRK phosphorylation are 
required for receptor/Gi coupling. Specifically we want to answer the following questions: 
a) Is Gi coupling agonist dose-dependent? 
b) Do agonist doses induce differential PKA and GRK phosphorylation of receptor in the 
cardiomyocytes? 
c) Do agonist doses influence receptor internalization for Gi coupling? 
d) What’s the role of PKA and GRK phosphorylation in receptor/Gi coupling? 
     We provide a new mechanism explaining β2AR coupling from Gs to Gi, which was agonist 
dose-dependent and controlled by both PKA and GRK phosphorylation of the receptor.  Our data 
also suggest that receptor trafficking is required for efficient Gi coupling.  
3) Effect of PKA and GRK phosphorylation on β2AR stability 
   Literature has suggested that maintenance of the β2AR level on the cell surface is important to 
provide the compensatory mechanism to improve cardiac performance (67). Loss of either PKA 
or GRK phosphorylation reduces β2AR recycling upon acute agonist stimulation shown by 
immunofluorescence detection (70, 84). It is also proposed that both lysosomes and proteasomes 
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coordinate to degrade the β2AR: extracellular domains are degraded in lysosomes and 
intracellular domains are degraded in proteasomes (4). In the current study, we extend our 
research to examine how PKA and GRK phosphorylation regulate β2AR stability under sustained 
agonist stimulation. We established HEK293 stable cell lines expressing wild type β2AR, PKA 
or GRK phosphorylation deficient β2AR and compared receptor the degradation over persistent 
agonist stimulation. We try to understand the following questions: 
1) Do PKA and GRK phosphorylation influence β2AR stability? 
2) Where are the receptors degraded? 
3) Is there any differential degradation of extracellular and intracellular domains of β2AR?  
      Our data suggest that both lysosomes and proteasomes coordinate to degrade extracellular 
and intracellular domains, respectively. Moreover, we find that alanine substitution in either 
PKA or GRK phosphorylation sites on β2AR leads to more rapid receptor degradation than wild 
type β2AR, which also becomes more lysosome-dependent, and less dependent on proteasome 
degradation pathway.  
     Together, these three post-translational modifications of β2AR coordinate to regulate receptor 
signaling in cardiac myocytes to prevent cells from overstimulation and maintain receptor level 
on the cell surface.  
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1.3 Figures 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1. GPCRs couple to different Gα proteins to activate diverse signaling (8).  
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Figure 1.2.  Schematic diagram of human β2AR (68).  
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Figure 1.3.  a) β arrestin 2-dependent β2AR endocytosis. 
                    b) The role of Rab GTPases in β2AR trafficking (86, 88).  
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CHAPTER   2 
 
Palmitoylation and GRK Phosphorylation Mediate the Association of β2 Adrenoceptor with 
Phosphodiesterase 4D/ β Arrestin 2 Complexes in Cardiomyocytes 
 
2.1   Abstract 
        β2 adrenergic receptor (β2AR) is a prototypical G-protein coupled receptor (GPCR) 
expressed in cardiomyocytes to regulate heart contraction through the classic cAMP-protein 
kinase A (PKA) signaling pathway. Among post-translational modifications, β2AR 
palmitoylation, the covalent acylation of cysteine residue 341, regulates cAMP levels and PKA 
phosphorylation of the receptor. However, how palmitoylation influences β2AR signaling 
remains unclear. Here, we demonstrate that in cardiomyocytes, palmitoylation is required for 
β2AR association with phosphodiesterase 4D isoforms to regulate cAMP-PKA activity. Mutation 
of cysteine 341 to alanine (β2AR-C341A) greatly reduces the association between the receptor 
and phosphodiesterase 4D9 at resting conditions, leading to higher baseline cAMP production 
and phosphorylation of β2AR-C341A by PKA. Upon stimulation, β2AR-C341A displays reduced 
recruitments of PDE4D5 and 4D8 compared to those of wild type β2AR, due to abolished 
association of β arrestin 2 to the mutant receptor.  Further studies show that recruitment of β-
arrestin 2 to β2AR is not only dependent on GRK phosphorylation of the receptor carboxyl tail, 
but also dependent on receptor palmitoylation.  Functionally, activation of β2AR-C341A results 
in a more sustained cAMP-PKA activity and higher myocyte contraction rate increase compared 
to those of wild type β2AR. Our data suggest that: 1) recruitment of β arrestin 2 to β2AR requires 
both GRK phosphorylation and palmitoylation of the receptor; 2) palmitoylation of β2AR 
facilitates the recruitment of β arrestin 2-PDE4D complexes to the receptor to control cAMP-
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PKA activity for fine-tuning cardiomyocyte contraction. 
 
2.2 Introduction 
      As a prototypical GPCR, β2AR plays important roles in cardiovascular and pulmonary 
physiology (68). Upon activation by catecholamines, β2AR couples to stimulatory Gs proteins, 
and activates adenylate cyclases to produce cAMP. The cAMP-dependent PKA phosphorylates 
various proteins in cardiomyocytes, such as phospholamban, L type calcium channel, and 
troponins, resulting in increased heart contraction force and rate (52). Interestingly, β2AR itself is 
also a substrate of PKA at serines 261/262 and G protein coupled receptor kinases (GRKs) at 
serines 355/356/364 in an agonist concentration-dependent manner (70, 110). Phosphorylation 
by GRKs leads to recruitment of cytosolic β arrestins to β2AR for receptor desensitization and 
internalization. Moreover, phosphorylation of β2AR by GRKs and PKA also play essential roles 
in β2AR/Gi protein coupling (70, 71).  
      Recent studies have revealed that besides regulation of βAR function through receptor 
phosphorylation, additional modulation of intracellular cAMP occurs through degradation with 
phosphodiesterases (PDEs), which is critical for βAR-mediated cardiomyocyte contraction 
response (111, 112). A βAR-induced intracellular cAMP equilibrium is generated via production 
through adenylate cyclases and degradation by PDEs (112). Through enzyme activity 
measurement and physiological relevance characterization, PDE4D families have been shown to 
be involved in βAR signaling in cardiomyocytes (55, 113). Nine PDE4D isoforms have been 
characterized, which have identical catalytic domains and unique regulatory domains for specific 
subcellular localization (114). Among the seven PDE4D isoforms expressed in cardiomyocytes, 
PDE4D5, PDE4D8 and PDE4D9 display differential association with β2AR at basal or 
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stimulating condition. However, the mechanisms of formation of these complexes and their 
specific functions remain to be addressed (115).   
     Over the last decade, the effect of post translational modifications on β2AR have been 
extensively studied, including the effect of phosphorylation on β2AR internalization and 
recycling (84, 85), ubiquitination on β2AR degradation (116), glycosylation on β2AR cell surface 
expression and degradation (69), hydroxylation on β2AR degradation (117), and palmitoylation 
on β2AR phosphorylation and signaling (78). Palmitoylation has been shown to target proteins 
such as Ras to the plasma membrane for signaling and function (118). The palmitoylation of 
β2AR occurs via covalent acylation of cysteine 341 and can be modulated by isoproterenol 
stimulation (76, 119). By loss of function study, palmitoylation was shown to be involved in 
basal phosphorylation of β2AR by PKA in Chinese hamster fibroblasts (120). However, the 
effect of palmitoylation on β2AR targeting, signaling, and function is not clearly understood, 
especially in physiological settings.  
  Here, we set out to study how β2AR palmitoylation influences receptor signaling in 
cardiomyocytes. Two specific questions were addressed: 1) is palmitoylation required for β2AR 
targeting to the plasma membrane? 2) Does palmitoylation of β2AR affect receptor association 
with downstream effectors in signaling complexes?  We find that palmitoylation is not required 
for β2AR targeting to lipid rafts on plasma membrane. Interestingly, mutant β2AR (C341A) 
lacking palmitoylation displays less association with PDE4D9 at resting conditions, which 
accounts for higher baseline cAMP and PKA phosphorylation of the receptor in cardiomyocytes. 
Furthermore, upon agonist stimulation, β2AR-C341A displays reduced association with PDE4D5 
and 4D8. This is because β2AR-C341A has reduced ability to recruit β arrestin 2, which scaffolds 
PDE4Ds to negatively modulate the receptor-induced cAMP level under the plasma membrane. 
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In conclusion, our data indicate that palmitoylation of β2AR is required for receptor association 
with PDE4Ds to confine cAMP level in cardiomyocytes for contraction response. 
2.3 Materials and Methods 
Site mutagenesis and adenovirus preparation 
     The mouse β2AR palmitoylation mutant (flag-β2AR-C341A) was generated through site 
directed mutagenesis of cysteine 341 of β2AR to alanine using pCDNA3.1-flag-β2AR as DNA 
template. The mutant was sequenced and subcloned into adenovirus vector pAdEasy-1 through 
recombination in bacteria BJ5831 for producing adenoviruses in HEK293-QBI cells. GRKmut-
β2AR whose GRK phosphorylation sites (serines 355, 356 and 358) were replaced with alanines 
had been described in previous study (70). Adenoviruses expressing PDE4D5-GFP, PDE4D8-
GFP or PDE4D9-GFP were created as described previously (11). Adenoviruses expressing 
adenylate cyclase isoform VI (AC-VI) had been reported previously (112).  
Neonatal cardiomyocytes isolation and total intracellular cAMP measurement 
      Single βAR or double βAR knockout mice were created in 1999 by Dr. Brian Kobilka’s 
research lab at Stanford University. Homologous knockdown of βARs is not embryonic or 
postnatal lethal. After maturing into adult mice, knockout mice did not show any abnormal 
behavior.  And both male and female mice are fertile (121, 122). In this study,   β1AR and β2AR 
double knockout (β1β2AR-KO) cardiomyocytes were isolated by  three steps digestion of 
neonatal mouse heart tissue with type II collagenase (Worthington, NJ) and cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM) supplied with 10% fetal bovine serum. After 
overnight culture, cells were washed once with phosphate buffered saline (PBS) to remove dead 
cells and then infected with adenoviruses expressing β2AR, β2AR-C341A or together with 
dominant negative PDE4D9 as described previously (115). 2-bromopalmitic acid (Sigma, MO)  
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which was used for inhibition of opioid receptor palmitoylation (123) was added to the cell 
culture 15 minutes before experiment at final concentration 100 μM. Rolipram was added at final 
concentration of 10 μM to inhibit total PDE4 activities in the cells.  Total intracellular cAMP 
was measured using cAMP HTS immunoassay kit (Millipore, MA).    
Radioligand binding assay 
      Neonatal cardiac cells cultured in 15 cm dishes overexpressing flag-β2AR or flag-β2AR-
C341A were washed once with cold phosphate buffered saline (PBS), harvested into hypotonic 
lysis buffer ( 20 mM HEPES, pH 7.4, 1 mM EDTA, 1 mM phenylmethyl- sulfonyl fluoride, and 
1 mM benzamidine). Cells were homogenized for 20 strokes in a tight homogenizer followed by 
centrifugation for 10 minutes at 800 x g to remove nuclei and unbroken cells.  The supernatant 
was further spun down for 20 minutes at 18000 rpm using a Beckman JC-M2 rotor to pellet the 
membrane, which was resuspended by passage through 25 Gauge needle in 1x binding buffer (75 
mM Tris-HCl, pH7.4, 12.5 mM MgCl2, 1 mM EDTA). After measuring the protein 
concentration by BCA assay (Pierce, IL), 20 μg of membrane protein containing β2AR  was 
incubated with 1 nM [3H] dihydroalprenolol (GE Healthcare, Piscataway, NJ) for 1 hour at room 
temperature at the shaken speed 230 rpm. 20 μg of membrane proteins from cardiac cells without 
overexpression of β2AR were used as control. Membranes were harvested and rinsed with 1x 
binding buffer. The membrane-bound [3H] dihydroalprenolol was detected using a Beckman LS 
6500 liquid scintillation counter (Beckman Coulter, Fullerton, CA). 
Receptor internalization and recycling 
       β1β2AR-KO cardiomyocytes were infected with adenoviruses expressing flag-β2AR, flag-
β2AR-C341A or flag-GRKmut-β2AR for 24 hours. Cells were serum starved for 30 minutes and 
then stimulated with 10 μM isoproterenol for different times as indicated to examine receptor 
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internalization. For determination of receptor recycling, cells were stimulated with 10 μM 
isoproterenol for 10 minutes followed by drug removal to allow receptor recycling for 30 
minutes and 60 minutes. Cells were fixed with 4% paraformaldehyde and permeabilized with 0.2 
% Nonidet P-40 and stained with anti-flag antibody M1 (mouse IgG2b, Sigma, MO) or together 
with caveolin-3 antibody against endogenous mouse caveolin 3 (mouse IgG1, BD, NJ). Images 
were visualized by Alex-488 conjugated mouse IgG1 or Alex-594 conjugated mouse IgG2b 
antibody (Invitrogen, CA) with a CCD camera on a Zeiss microscope with MetaMorph software.   
Quantification of receptor internalization and recycling using FLISA method has been described 
in previous studies (70).  
Purification of caveolin-rich membrane fraction 
     Neonatal cardiomyocytes overexpressing flag-β2AR or flag-β2AR-C341A were collected into 
cold PBS and harvested by centrifugation. Cells were resuspended in 2 ml 0.5 M sodium 
carbonate (pH~11). After gentle vortexing, 1.75 ml sample was mixed with 1.75 ml  80% 
sucrose buffer ( 25 mM MES, pH 6.5, 0.15 M NaCl, 80% sucrose) and loaded on the bottom of 
ultracentrifuge tube. A two-step gradient was loaded on the top of the sample with 3.5 ml 35% 
sucrose buffer (25 mM MES, 0.15 M NaCl, 250 mM sodium carbonate, 35% sucrose)  and 4 ml 
5% sucrose buffer ( 25 mM MES, 0.15 M NaCl, 250 mM sodium carbonate, 5% sucrose).  
Sample was spun down in a Beckman SW41 rotor for 18 hours at 38000 rpm. 1ml fraction was 
collected from top to bottom and mixed with 10% trichloroacetic acid for protein precipitation 
for 4 hours on ice. The protein pellet was also dissolved in 1x SDS-sample buffer. Proteins after 
precipitation was collected by centrifugation for 30 minutes at 13200 rpm, washed twice with 
100% cold acetone and dissolved in 1x SDS-sample buffer. Proteins were separated by 12% 
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SDS-PAGE for detection of caveolin-3 by caveolin-3 antibody (BD, NJ) and β2AR or β2AR-
C341A by anti-flag antibody (Sigma, MO).  
Co-immunoprecipitation and Western blot 
     Neonatal cardiomyocytes overexpressing flag-β2AR, flag-β2AR-C341A, flag-GRKmut-β2AR 
or together with individual PDE4D-GFP isoforms, GFP-β arrestin 2, were stimulated with 10 μM 
isoproterenol and harvested in lysis buffer (20 mM HEPES, pH 7.4, 0.6% Nonidet P-40, 150 mM 
NaCl, 2 mM EDTA, 10% glycerol, 0.03% n-Dodecyl-β-D-maltoside (Enzo Life Sciences, PA),  
1 mM PMSF, 1 mM Benzamidine, 1 mM NaF, 1 mM Na3VO4). Protein samples were lysed for 
40 minutes at 4°C before centrifugation for 10 minutes at 800 x g to collect the supernatant. 
Receptors were immunoprecipitated by anti-flag M2 affinity resin (Sigma, MO) for 2 hours at 
4°C and eluted into 2x SDS-sample buffer for SDS-PAGE. After transfer onto nitrocellulose 
membrane, proteins were blotted with 5% non-fat milk in 1x TBST and subsequently blotted 
with the following antibodies: endogenous PDE4 (Abcam, CA), GFP (Clontech, CA), anti-flag 
(Sigma, MO), caveolin-3 (BD, NJ). The optical density of the bands was analyzed with ImageJ 
(National Institute of Health, MD, USA).  
Receptor phosphorylation  
     Cardiomyocytes expressing flag-β2AR or flag-β2AR-C341A were serum starved for 30 
minutes before stimulation by 10 μM isoproterenol for different times as indicated. Proteins were 
harvested and subjected to SDS-PAGE for Western blot detection of phosphorylation of β2AR by 
protein kinase A on serines 261/262 (mouse monoclonal antibody, a kind gift from Dr. Richard 
Clark, University of Houston, TX), G-protein coupled receptor kinases on serines 355/356/358 
(SCBT, CA), total β2AR by anti-flag M1 antibody.   
Fluorescence resonance energy transfer (FRET) 
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     The detailed procedures to measure real time cAMP/PKA activity in living cardiomyocytes 
using the FRET technique has been described in previous study (111). In brief, β1β2AR-KO 
neonatal cardiomyocytes were infected with adenoviruses expressing β2AR or β2AR-C341A, 
along with cAMP FRET biosensor ICUE3 (indicator of cAMP using Epac) or PKA FRET 
biosensor AKAR (A kinase activity reporter). After overnight expression, cells were washed 
twice with PBS and challenged by 10 μM isoproterenol. Fluorescence images were taken every 
20 seconds and the ratio between emission of YFP and that of CFP  was plotted as an indicator 
of dynamic activity change which was automatically calculated by Metafluor software. Basal 
line substraction was performed using Origin software. Data analysis was performed by 
GraphPad Prism software.  
Statistical analysis 
All statistical analyses were performed using GraphPad Prism software. P < 0.05 was 
considered statistically significant.  
2.4 Results 
Palmitoylation of cysteine 341 of β2AR is not required for receptor targeting to plasma 
membrane caveolae  
     Palmitoylation of various proteins has been shown required for protein targeting to plasma 
membrane (124-126). In our study, mutation of β2AR palmitoylation residue cysteine 341 to 
alanine (β2AR-C341A) did not change its cell surface expression level at basal conditions 
measured by [3H] dihydroalprenolol binding at saturation concentration (Fig. 2.1A). β2AR has 
been shown localized in caveolae/lipid raft for proper signaling and cell physiology (127). Both 
β2AR and β2AR-C341A were localized in caveolae-rich membrane fractionation which was 
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further supported by partial co-localization and co-immunoprecipitation between receptor and 
caveolin-3 (Fig. 2.1B-D).  
β2AR-C341A has reduced association with PDE4 leading to higher intracellular cAMP and PKA 
phosphorylation at serines 261/262 at resting conditions 
       Previous study of β2AR palmitoylation in Chinese hamster fibroblasts has shown that 
mutation of the palmitoylation residue reduces β2AR’s ability to activate adenylate cyclases for 
cAMP production (76). To evaluate the effect of mutant β2AR on receptor signaling without 
complication of the endogenous receptors, we used cardiomyocytes lacking both β1 and β2AR 
genes (β1β2AR-KO), and compared the cAMP signaling induced by β2AR or β2AR-C341A at 
resting and stimulation conditions. At equivalent expression levels, β2AR-C341A led to higher 
cAMP signals than that of β2AR (Fig. 2.2A) at both basal and stimulating conditions. 
Pretreatment with the palmitoylation inhibitor 2-bromopalmitic acid to block β2AR 
palmitoylation enhanced the increase in cAMP production in cells expressing β2AR but not that 
of β2AR-C341A after isoproterenol stimulation (Fig. 2.2B), indicating that loss of palmitoylation 
of β2AR impairs the receptor-induced cAMP signals. In agreement, β2AR-C341A displayed 
higher basal phosphorylation by PKA at serines 261/262 than that of wild type β2AR (Fig. 2.2C). 
These data indicate that β2AR-C341A either has increased stimulation of adenylate cyclases for 
cAMP production or has decreased rate of cAMP degradation mediated by β2AR-associated 
PDE4D. We then tested these hypotheses. Interestingly, β2AR-C341A displayed a reduced 
association with phosphodiesterase 4 in both HEK293 cells and neonatal cardiomyocytes (Fig. 
2.2E-F), supporting a role of phosphodiesterase 4 association with β2AR in modulating cAMP 
level induced by β2AR-C341A in cardiomyocytes. In contrast, mutation of β2AR palmitoylation 
residue did not change its association with adenylate cyclase VI, one of the two major adenylate 
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cyclase isoforms expressed in cardiomyocytes (Fig. 2.2D). 
β2AR-C341A has reduced association with PDE4D isoforms at both resting and stimulating 
conditions      
     We have previously reported differential association of PDE4D isoforms with β2AR in 
cardiomyocytes at resting and stimulating conditions (115). The effect of palmitoylation of β2AR 
on these complexes formation was examined.  Cardiomyocytes were infected with adenoviruses 
expressing β2AR or β2AR-C341A along with individual PDE4D isoforms; and their association 
was examined by co-immunoprecipitation using antibody against the receptors. β2AR-C341A 
displayed less association with PDE4D9 at basal conditions, the major PDE4D isoform in 
receptor complex at resting conditions (Fig. 2.3A and (115)). Overexpression of dominant 
negative PDE4D9 containing only the N terminus and regulatory domains led to increased 
production of cAMP in cells expressing β2AR but not those expressing β2AR-C341A (Fig. 2.3B). 
As a positive control, inhibition of all PDE4 enzymes with rolipram further increased cAMP 
accumulation. Upon agonist stimulation, recruitments of PDE4D5, 4D8 and 4D9 to β2AR-
C341A were significantly reduced compared to those of wild type β2AR (Fig. 2.4), indicating the 
necessary role of palmitoylation for association of PDE4D isoforms with activated β2AR at 
stimulating conditions.  
β2AR palmitoylation mediates the association of receptor with PDE4D through β arrestin 2 
      The association between β2AR and PDE4D enzymes is indirect and dependent on scaffold 
protein β arrestins (115, 128). In cardiomyocytes, β arrestin 2 has abundant expression whereas β 
arrestin 1 expression is low (Fig. 2.5A). To investigate the underlining mechanism of reduced 
association of PDE4D enzymes with β2AR-C341A, β2ARs and β arrestin 2-GFP were expressed 
in β1β2AR-KO cardiomyocytes, and their interaction was examined by co-immunoprecipitation. 
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As shown in Fig. 2.5B, upon agonist stimulation, recruitment of β arrestin 2 to β2AR-C341A was 
significantly reduced compared to that of wild type β2AR. Furthermore, pretreatment with 2-
bromopalmitic acid abolished the recruitment of β arrestin 2  and PDE4D5 to the receptor (Fig. 
2.5C-D), indicating that loss of palmitoylation rather than alanine mutation leading to receptor 
conformation change that resulted in reduced recruitment of β arrestin 2/PDE4D complexes. 
Meanwhile, phosphorylation of β2AR by GRKs on serines 355/356/358 is also crucial for 
mediating recruitment of β arrestin 2 to uncouple β2AR from G proteins (85). In agreement, we 
showed that mutation of GRK phosphorylation residues greatly reduced the association between 
β2AR and β arrestin 2/PDE4D complexes (Fig. 2.5E-F). Together, these data suggest that 
recruitment of β arrestin 2 to β2AR requires not only β2AR phosphorylation by GRKs but also 
β2AR palmitoylation.      
      Based on the data above, we expect that mutations on either palmitoylation (C341A) or GRK 
phosphorylation (GRKmut) would abolish the agonist-induced β2AR internalization. As 
expected, mutation of all GRK phosphorylation sites on β2AR led to reduced receptor 
internalization upon stimulation with 10 μM of isoproterenol, similar to those reported 
previously   (Fig. 2.6A and (70)). These data were also confirmed by quantitative measurement 
of cell surface receptor level (Fig. 2.6D). In contrast, β2AR with palmitoylation site mutation 
displayed normal time-dependent internalization similar to that of wild type receptor upon 
isoproterenol stimulation (Fig. 2.6A). Both wild type receptor and C341A mutant also displayed 
rapid recycling upon removal of isoproterenol. The immunofluorescence staining was further 
confirmed by quantification with antibody labeling (Fig. 2.6B and 2.6C). Consistent with 
trafficking properties, β2AR-C341A displayed normal phosphorylation by GRKs in comparison 
to the wild type β2AR upon isoproterenol stimulation (Fig. 2.6E). However, PKA 
26 
 
phosphorylation of β2AR-C341A was more sustained compared to that of wild type β2AR (Fig. 
2.6E).  
β2AR-C341A induces higher and sustained signaling for myocyte contraction 
     We further examined the cAMP/PKA signaling induced by the β2AR-C341A mutant lacking 
the palmitoylation site. By using fluorescence energy resonance transfer (FRET) to measure real-
time cAMP, we showed that upon isoproterenol stimulation, the cAMP signal induced by β2AR-
C341A was slightly higher and more sustained than that of β2AR (Fig. 2.7A).  Pretreatment with 
2-bromopalmitic acid enhanced the cAMP production upon β2AR activation but not that of 
β2AR-C341A (Fig. 2.7B-D), consistent with the observed effects on cAMP accumulation at basal 
conditions (Fig. 2.2B).  Pretreatment with PDE4 inhibitor rolipram almost abolished the 
difference of cAMP induced by β2AR and β2AR-C341A (Fig. 7B-D). Inhibition of Gi with 
pertussis toxin (PTX) enhanced the cAMP FRET response induced by either β2AR-C341A or 
wild type receptor, indicating that receptor/Gi coupling is not inhibited by palmitoylation 
mutation (Fig. 2.7D). In agreement with cAMP data, PKA activity induced by β2AR-C341A was 
also found to be sustained which led to sustained receptor phosphorylation at serines 261/262 
(Fig. 2.7E and Fig. 2.6E). 2-bromopalmitic acid treatment further increased the PKA activity but 
not that of β2AR-C341A, consistent with cAMP FRET data (Fig. 2.7E). As a result, activation of 
β2AR-C341A led to higher increase in myocyte contraction rate than that of wild type β2AR, 
which is not influenced by further incubation with 2-bromopalmitic acid (Fig. 2.7F).  
2.5 Discussion  
      Palmitoylation is a common feature shared by many G-protein coupled receptors. In the 
present study, we demonstrate that palmitoylation of β2AR is required for receptor interaction 
with β arrestin 2 upon agonist stimulation, which scaffolds PDE4D enzymes to regulate cAMP 
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level in cardiomyocytes. This study reveals a novel mechanism of how palmitoylation influences 
the receptor complex by modulating the receptor association with other signaling proteins, which 
in turn fine-tunes the level of receptor-induced second messenger cAMP for PKA activation and 
subsequent physiological contraction responses.       
 We find that mutation of palmitoylation site on β2AR or inhibition of palmitoylation greatly 
enhances the cAMP signal and receptor phosphorylation by PKA in cardiomyocytes at basal 
conditions (Fig. 2.2A-C), consistent with higher PKA phosphorylation of β2AR expressed in 
Chinese hamster fibroblasts (120, 129). Similarly, it has been shown that overexpression of 
palmitoylation-deficient rhodopsin in transgenic mice results in hyperphosphorylation of 
palmitoylation-deficient  rhodopsin, which reduces rod’s sensitivity to light (130). Moreover, we 
show that the enhanced receptor phosphorylation is primarily due to the reduced PDE4D9 
association with β2AR to degrade cAMP in the vicinity of receptor complexes.  
 Upon stimulation, β2AR-C341A displays reduced association with PDE4D isoforms (Fig. 2.4). 
The reduced PDE4D association contributes to a more sustained cAMP production (Fig. 2.7). 
This appears to be different from the previous observation that β2AR palmitoylation mutant has 
impaired ability to promote activation of G proteins and adenylate cyclases, resulting in less 
cAMP production in Chinese hamster fibroblasts (76). Our data indicate that in cardiomyocytes, 
despite a possible reduced cAMP production, the PDE4D-mediated cAMP degradation is more 
critical in controlling cAMP dynamics; and the reduced receptor association of PDE4Ds not only 
offsets the reduced cAMP production but also promotes a sustained cAMP signal. Additionally, 
previous studies show that the β2AR/Gs protein coupling occurs at a fast kinetics within less than 
100 ms (131), whereas the agonist-induced increase in β2AR palmitoylation is barely detectable 
at 2 minutes, and only reaches a peak level at 60 minutes (119). These observations further argue 
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for additional roles of agonist-induced palmitoylation in anchoring/organizing receptor 
complexes with other signaling molecules such as PDE4Ds, besides modulating receptor/G 
protein coupling. Indeed, under inhibition of PDE4 with rolipram, both wild type β2AR and 
β2AR-C341A induce equivalent cAMP increases in cardiomyocytes (Fig. 2.7B-C).  
Agonist-induced association between PDE4Ds and β2AR depends on scaffold protein β 
arrestins (128).  Mutation of the palmitoylation site or blocking palmitoylation of β2AR by 2-
bromopalmitic acid treatment abolished the recruitment of β arrestin 2/PDE4D to β2AR upon 
agonist stimulation, similar to the effect of palmitoylation on activated vasopressin receptor (132) 
(Fig. 2.5B). This is direct evidence showing that besides GRK phosphorylation, palmitoylation 
of β2AR is also necessary in recruitment of β arrestin 2 to the receptor. While GRK 
phosphorylation of the carboxyl tail of β2AR is required for recruitment of β arrestin 2 to β2AR 
for receptor internalization leading to receptor desensitization (85), β2AR-C341A displays 
normal phosphorylation by GRKs and internalization upon agonist stimulation without any 
increase in binding of β arrestin 2 (Fig. 2.6E and Fig. 2.5B). These data indicate that the binding 
of GRKs to receptor complexes or the residues phosphorylated by GRKs may offer additional 
function necessary for receptor internalization. In supporting this notion, GRK2 may recruit 
PI3K via protein-protein interaction, controlling β2AR internalization by regulating formation of 
clathrin-coated pits (133). Our data also suggest that the baseline binding of arrestins to β2AR is 
sufficient for receptor internalization in cardiomyocytes. In contrast, the recruitment of β arrestin 
2 to β2AR is necessary for forming receptor complexes with PDE4D isoforms to restrict cAMP 
signaling; this is dependent on two separate events: receptor phosphorylation by GRKs and 
receptor palmitoylation on cysteine 341.  
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There is abundant evidence on the role of palmitoylation in targeting or anchoring other 
proteins into lipid rafts, such as G protein signaling proteins (RGS) (134), G proteins (135), 
SNAP proteins (136), and Ras proteins (118). Studies from β2AR as well as the δ opioid receptor 
have shown that GPCR palmitoylation happens early in the receptor biosynthetic pathway and is 
increased by short time agonist stimulation (123, 129). Our data indicate that palmitoylation of 
β2AR is not required for receptor targeting to caveolae/lipid rafts on plasma membrane, similar 
to the early studies showing that mutation of palmitoylation sites on caveolin 1 does not affect 
the targeting of the proteins in lipid rafts and caveolae (137). Palmitoylation of β2AR has also 
been proposed to stabilize helix 8 between the transmembrane domain and cysteine residue, 
which contains a putative binding motif for caveolin 1 (138). However, our data indicate that 
palmitoylation of β2AR is not required for the receptor association with caveolin. Interestingly, 
our data show that the mutation on the palmitoylation site did not affect the receptor 
phosphorylation by GRK at serine 355/356/358, indicating that the recognition of these residues 
by GRK is preserved, which differs from the interaction between the receptor and arrestin. 
Therefore, our data suggest that the interaction between β2AR and arrestin requires additional 
receptor sequence structure besides GRK phosphorylation, and that palmitoylation may stabilize 
a favorable structure for binding to arrestin. Further studies are required to dissect how this 
modification affects the receptor structural properties for divergent biochemical and cellular 
processes, including binding to caveolin, arrestin, and phosphorylation by PKA and GRK at the 
basal and stimulation conditions.  
  Activation of β2AR signaling plays important roles in mediating cardiomyocyte contraction. 
This study unveils another mechanism of fine tuning β2AR signaling in cardiomyocytes. At basal 
conditions, β2AR palmitoylation mediates receptor association with PDE4D9 to modulate basal 
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cAMP-PKA activity for cardiac performance. Under stress conditions, increased circulating 
catecholamines activate β2AR leading to two post-translational modifications of the receptor: 
First, receptor phosphorylation by GRKs leads to receptor desensitization through endocytosis; 
Secondly, receptor palmitoylation, together with GRK phosphorylation, results in recruitment of 
the β arrestin 2-PDE4D complex to the receptor to reduce cAMP-PKA activity. Both 
modifications act as protective mechanisms to prevent cardiomyocytes from overstimulation by 
catecholamines.     
 Together, we have shown that palmitoylation of β2AR significantly influences receptor 
signaling in cardiomyocytes via modulating the receptor associated complexes. It is necessary to 
maintain a basal level association with PDE4D9, as well as enhance the receptor association with 
PDE4D5 and 4D8 upon agonist stimulation. These complexes potentially limit the cAMP 
signaling in local environments, which not only contributes to receptor signaling specificity, but 
also protects cells from overstimulation.  
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2.6 Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1. Palmitoylation is not required for β2AR targeting to plasma membrane caveolae. 
β1β2AR-KO cardiomyocytes were infected with adenoviruses expressing flag-β2AR or flag-β2AR-C341A for 24 
hours. A) 20 μg membrane protein containing β2AR was incubated with 1 nM [3H] DHA to measure cell surface 
expression level of β2AR and β2AR-C341A. B) Membrane fractionations were blotted with caveilin-3 and anti-flag 
antibodies. C)  Cell lysates were incubated with M2 beads for immunoprecipitation of flag-β2AR or flag-β2AR-
C341A to detect endogenous caveolin-3 association. D) After fixation and permeabilization, cells were double 
stained with anti-flag and caveolin-3 antibodies to detect receptors and endogenous caveolin-3 for confocal 
microscope images. All the data are from at least three experiments. 
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Figure 2.2. Palmitoylation is required for β2AR association with phosphodiesterase 4. 
β1β2AR-KO cardiomyocytes were infected with adenoviruses expressing flag-β2AR or flag-β2AR-C341A for 24 
hours. A-B) Total intracellular cAMP was measured using cAMP HTS immunoassay kit. 2-bromopalmitic acid was 
added 15 minutes before cAMP assay. C) Phosphorylation of β2AR or β2AR-C341A by PKA on serines 261/262 
was detected by phospho-serines 261/262 specific antibody. D) β 1β2AR-KO cardiomyocytes were double infected 
with adenoviruses expressing flag-β2AR or flag-β2AR-C341A together with adenylate cyclase VI. Cell lysates were 
immunoprecipitated with M2 beads to isolate the receptor complex. Receptor and associated adenylate cyclase VI 
were detected in Western blot.  E) HEK293 cells or F) neonatal cardiomyocytes transiently expressing flag-β2AR or 
flag-β2AR-C341A were lysed and incubated with M2 beads for co-immunoprecipitation of endogenous 
phosphodiesterase 4.   *, p < 0.05 by t-test.  
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Figure 2.3 Palmitoylation mutation reduces the association between PDE4D9 and β2AR at 
basal condition.  
 β1β2AR-KO cardiomyocytes were infected with adenoviruses expressing flag-β2AR or flag-β2AR-C341A together 
with GFP-tagged PDE4D proteins for 24 hours. A) Cell lysates were incubated with M2 beads to immunoprecipitate 
flag-β2AR and flag-β2AR-C341A. Proteins eluted from the beads were subjected to SDS-PAGE for detection of 
receptors by M1 antibody and GFP-tagged PDE4D proteins by GFP antibody. *, p < 0.05 by t-test. B) Total 
intracellular cAMP in cells expressing β2ARs or together with DN-4D9 was measured by cAMP measurement kit. 
Rolipram was added at final concentration10 μM.  *, p < 0.05 by t-test. 
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Figure 2.4. Palmitoylation of β2AR is required for association with PDE4D isoforms upon 
activation of the receptors. 
β1β2AR-KO cardiomyocytes expressing flag-β2AR or flag-β2AR-C341A together with PDE4D-GFPs were 
stimulated with 10 μM isoproterenol for indicated times. Cell lysates were incubated with anti-flag M2 beads to 
immunoprecipitate flag-β2AR and flag-β2AR-C341A. Proteins eluted from beads were subjected to SDS-PAGE for 
detection of receptors by M1 antibody and GFP-tagged PDE4D proteins by GFP antibody. *, p < 0.05 by t-test 
against control without stimulation. 
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Figure 2.5. Both GRK phosphorylation and palmitoylation of β2AR are required for the 
recruitment of β arrestin 2/PDE4D complexes. 
A) Detection of endogenous β arrestin 1 and β arrestin 2 in cardiomyocytes by β arrestin 1 and β arrestin 2 antibodies. 
Lane 1, cell lysate from HEK293 cells transiently expressing β arrestin 1-GFP; Lane 2, cell lysate from HEK293 
cells transiently expressing β arrestin 2-GFP; Lane 3, cell lysate from neonatal cardiomyocytes. B-F) Lysates from 
cardiac cells transiently expressing flag-β2AR, flag-β2AR-C341A or flag-GRKmut-β2AR together with β arrestin 2-
GFP, PDE4D5-GFP were incubated with M2 beads to immunoprecipitate flag-tagged receptors. Proteins were 
subject to SDS-PAGE to detect receptors and GFP-tagged β arrestin 2 or PDE4D5.  2-bromopalmitic acid was added 
15 minutes before Iso stimulation at 100 nM to inhibit receptor palmitoylation. Quantification of the data was based 
on at least 5 experiments. *, p < 0.05 by t-test against control without stimulation.  
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Figure  2.6.  Mutation of palmitoylation at cysteine 341 does not affect β2AR trafficking. 
 A) Cells were stimulated with 10 μM isoproterenol to examine receptor internalization or followed by agonist 
removal to examine receptor recycling.  Receptors were stained by anti-flag antibody M1. B-D) Receptors 
remaining on the cell surface after internalization (B and D) or recycling (C) were quantified using antibody labeling. 
1, control; 2, 10 minutes of Iso stimulation; 3, 10 minutes of Iso stimulation followed by 30 minutes receptor 
recycling; 4, 10 minutes of Iso stimulation followed by 60 minutes receptor recycling. *, p < 0.05 by t-test. E) 
Cardiomyocytes expressing flag-β2AR or flag-β2AR-C341A were stimulated with 10 μM isoproterenol for different 
times to detect receptor phosphorylation by PKA on serines 261/262 or GRKs on serines 355, 356 and 358. *, p < 
0.05 by two-way ANOVA. 
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Figure 2.7. Stimulation of flag-β2AR-C341A leads to higher and sustained cAMP-PKA 
activity and cardiomyocyte contraction rate increase. 
β1β2AR-KO cardiomyocytes were infected with adenoviruses expressing β2AR or β2AR-C341A, along with cAMP 
FRET biosensor ICUE3 (A-C) or PKA activity biosensor AKAR 2.2 (D). (A-C) Cells were stimulated with 
isoproterenol (10 μM) to record the changes of FRET ratio.  2-Bro, 2-bromopalmitic acid (100 nM) was added 15 
minutes before Iso stimulation; Roli, rolipram was added together with Iso at 10 μM; PTX, pertussis toxin (300 
ng/ml) was added 2 hours before Iso stimulation. ***, p < 0.001 by two-way ANOVA; ###, p < 0.001 by two- way 
ANOVA against control without inhibitor treatment. D-E) Quantification of cAMP or PKA activity FRET. 
Statistical analysis is performed against wild type β2AR without treatment.  F) Quantification of cardiomyocyte 
contraction rate increase upon Iso stimulation or together with 2-bromopalmitic acid treatment.  Statistical analysis 
is performed against wild type β2AR without treatment. 
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CHAPTER   3 
 
Agonist Dose-Dependent PKA and GRK Phosphorylation Regulate β2 Adrenoceptor 
Coupling to Gi Proteins in Cardiomyocytes 
 
3.1 Abstract 
     Adrenergic receptors (ARs) play a pivotal role in regulating cardiovascular response to 
catecholamines during stress. β2ARs, prototypical G protein-coupled receptors (GPCRs) 
expressed in animal hearts, display dual-coupling to both Gs and Gi proteins to control the 
adenylyl cyclase-cAMP dependent protein kinase A (PKA) pathway to regulate contraction 
responses. Here, we showed that the β2AR coupling to Gi proteins was agonist dose-dependent 
and occurred only at high concentrations of agonist in mouse cardiac myocytes. Both the β2AR-
induced PKA activity, measured by fluorescence resonance energy transfer (FRET) imaging, and 
the increase in myocyte contraction rate displayed sensitivity to the Gi inhibitor pertussis toxin 
(PTX). Further studies revealed that activated β2ARs underwent PKA phosphorylation at a broad 
range of agonist concentrations. Disruption of the PKA phosphorylation sites on the β2AR 
blocked receptor/Gi coupling. However, a sufficient β2AR/Gi coupling was also dependent on the 
G-protein receptor kinase (GRK)-mediated phosphorylation of the receptors, which only 
occurred at high concentrations of agonist (≥ 100 nM). Disruption of the GRK phosphorylation 
sites on the β2AR blocked receptor internalization and coupling to Gi proteins, likely by 
preventing the receptor’s transportation to access Gi proteins. Furthermore, receptors mutated at 
neither PKA- nor GRK-sites did not display sensitivity to the Gi specific inhibitor, GiCT. 
Together, our studies revealed distinct roles of PKA and GRK phosphorylation of the β2AR for 
agonist dose-dependent coupling to Gi proteins in cardiac myocytes, which may protect cells 
from overstimulation under high concentrations of catecholamines. 
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 3.2 Introduction 
      Adrenergic receptors (ARs) play a pivotal role in regulating cardiovascular response to 
catecholamines during stress. Both β1 and β2ARs are prototypical GPCRs expressed in animal 
hearts, which mediate the increases in cardiac contraction upon agonist stimulation through the 
Gs-adenylyl cyclase-cAMP dependent PKA pathway (139). β2ARs are also known to uniquely 
couple to inhibitory Gi proteins, which inhibits adenylyl cyclases to reduce cardiac contraction, 
and initiates anti-apoptotic and cell growth signaling (140, 141). While β2AR coupling to Gi has 
been studied in reconstituted systems and in fibroblasts (142, 143),  little is known about the 
regulation process and circumstances under which this coupling occurs in cardiac cells, along 
with its physiological consequences.  
Various studies indicate that phosphorylation of β2AR plays a critical role in regulating 
differential G protein-coupling. The β2AR phosphorylation by PKA mediates the switch of 
coupling from Gs to Gi (71, 144), presumably operating in a feedback loop after receptor 
activation. Our previous studies have revealed that β2AR/Gi coupling is also dependent on 
receptor internalization and recycling (108, 145). Meanwhile, Wang et al. has showed that direct 
inhibition of GRK2 prevents β2AR/Gi coupling in mouse cardiac myocytes (108), supporting a 
role of the β2AR phosphorylation by GRK in receptor/Gi coupling.  
Studies have also revealed that β2ARs are differentially phosphorylated by PKA and GRK in 
fibroblasts in an agonist dose-dependent manner (109, 110, 146, 147). While the PKA-mediated 
phosphorylation is sensitive to stimulation with sub-nanomolar concentrations, the GRK-
mediated phosphorylation happens only when β2ARs are stimulated with saturated 
concentrations (109, 110, 146, 147). This differential regulation of receptor phosphorylation by 
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different kinases and their effects on subsequent receptor trafficking indicate that the β2AR/Gi 
coupling may be finely regulated in an agonist concentration-dependent manner.  
Here, using fluorescence resonance energy transfer (FRET) assay with a biosensor for PKA 
activity, and a physiological cardiac contraction rate assay, we show for the first time that 
β2AR/Gi coupling occurs only at a saturated concentration of isoproterenol (Iso) in cardiac cells.  
Stimulation induces the PKA-mediated phosphorylation of the β2AR over a wide range of 
agonist concentrations, whereas the GRK-mediated phosphorylation occurs only at sufficiently 
high concentrations (≥ 100 nM) of Iso, and is necessary for receptor internalization. We further 
demonstrate that mutations of the specific PKA or GRK phosphorylation sites on the β2AR 
abolish receptor coupling to Gi protein.  Our data support the conclusion that the PKA-mediated 
phosphorylation is necessary for β2AR/Gi coupling, but a sufficient receptor/Gi coupling is also 
dependent on the GRK-mediated phosphorylation and subsequent trafficking of the receptors.  
3.3 Materials and Methods 
Site-directed mutagenesis and recombinant adenoviruses  
     pcDNA3.1-flag-mβ2AR was used as a template for site mutagenesis. A PKAmut β2AR 
lacking protein kinase A (PKA) phosphorylation sites (serines 261, 262, 345, 346) was generated 
by replacing the four serines with alanines using the PCR method.  A GRKmut-β2AR lacking the 
GRK phosphorylation sites (serines 355, 356, and 358) was also created by replacing serines 
with alanines. These phosphorylation sites had been determined and confirmed by Tran et al. 
(110). Both β2AR mutants were sequenced, and transformed into adenovector pAdEasy-1 which 
is an adenovirus replication deficient vector for producing adenoviruses in HEK293-QBI cell 
background as previously described (148). Viruses were purified by CsCl equilibrium density 
gradient centrifugation overnight in a SW25 rotor. The titers of the viruses were assessed by 
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comparison of receptor expression levels with both western blots and ligand binding using [3H] 
dihydroalprenolol as previously described (149). The GFP-GiCT virus used in contraction assays 
was a kind gift from Dr. Walter Koch (Thomas Jefferson University, Philadelphia, PA).  
Cardiac myocyte contraction assay  
  Measurement of spontaneous myocyte contraction was performed as described previously 
(150). In brief, neonatal cardiac myocytes were isolated from mice lacking either β1AR (β1AR-
KO) or both β1 and β2AR genes (β1β2AR-KO) using collagenase type II and cultured in DMEM 
supplied with 10% fetal bovine serum. After overnight culture, β1β2AR-KO myocytes were 
washed with PBS to remove dead cells and then infected with murine β2AR, PKAmut-β2AR, or 
GRKmut-β2AR at moi of 100 for 24 hours, and stimulated with 10 μM of Iso. To inhibit Gi 
proteins, cardiac myocytes were treated with Gi inhibitor pertussis toxin (PTX) at 0.3μg /ml 3 
hours before stimulation. GFP-GiCT virus was co-infected at 100 moi, or as indicated, together 
with the wild-type or mutant β2AR viruses. Contraction rate assays were performed the next day 
by monitoring contraction rate every minute before and after Iso stimulation as described 
previously (150).  
Receptor phosphorylation 
     Neonatal cardiac myocytes were infected with adenoviruses expressing flag-tagged wild-type 
or mutant β2ARs at moi of 100. 48 hours later, cells were serum starved for 2 hours and 
stimulated with different doses of Iso for 5 min. For the time course experiments, cells were 
stimulated with 10 μM of Iso for different times as indicated. Cells were harvested into lysis 
buffer (10 mM Tris pH 8.0, 1% NP40, 150 mM NaCl, 2 mM EDTA, protease and phosphatase 
inhibitor cocktail (Thermo Scientific, IL) for 30 min at 4 °C. Samples were centrifuged for 10 
minutes at 16100 x g, and the supernatant was resolved by SDS-PAGE for western blotting. The 
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β2AR phosphorylation by PKA at serines 261 and 262 was detected with a monoclonal antibody 
from Dr. Richard Clark (the University of Texas Health Science Center, Houston, TX). The 
β2AR phosphorylation by GRK at serines 355, 356 and 358 was detected with a polyclonal 
antibody from Santa Cruz Biotechnology (SCBT, CA). IRDye 680CW goat anti-mouse and 
IRDye 800CW goat anti-rabbit secondary antibodies (Li-cor Biosciences, NE) were used to 
detect pS261/262 and pS355/356 phosphorylation respectively. Western blots were visualized 
with an Odyssey scanner (Li-cor Biosciences, Lincoln, NE), and quantified before normalization 
against the baseline levels using NIH ImageJ. 
Receptor internalization and recycling  
  β1β2AR-KO myocytes expressing flag-β2ARs were serum starved for 2 hours and stimulated 
with 10 nM or 10 μM of Iso for different time periods. For receptor recycling, cells were 
stimulated with Iso for 10 min, rinsed, and re-fed with serum free media for different time. Cells 
were fixed with 4% paraformaldehyde and permeabilized with 0.2% Nonidet P-40, and stained 
with anti-flag antibody, which was revealed with an Alexa-488 conjugated goat anti-mouse 
antibody (Invitrogen, CA). Fluorescence images were taken with a CCD camera on a Zeiss 
microscope with MetaMorph software. To quantify receptor internalization and recycling, 
HEK293 cells were transfected with plasmids expressing the flag-β2AR, PKAmut β2AR, and 
GRKmut β2AR. Receptor internalization and recycling were quantified in HEK293 cells by 
using a Fluorescence-linked immunosorbent assay (FLISA)  to determine cell surface receptor 
levels after internalization and recycling as previously described (151). In brief, HEK293 cells 
expressing flag-tagged receptors were incubated with anti-flag M1 antibody followed by 
incubation with Alexa-488 goat-anti-mouse secondary antibody. Fluorescence absorbance was 
detected by Spectramax M2 fluorometer. 
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PKA activity measurement through FRET assay  
      β1AR-KO or β1β2AR-KO cardiac myocytes were infected overnight with adenovirus 
expressing A-Kinase Activity Reporter (AKAR 2.2) at 100 moi as previously described (111). 
For β1β2AR-KO myocytes, cells were also infected with β2AR viruses for overnight expression. 
Procedures for PKA FRET activity were carried out as previously described (111). In brief, cells 
were washed with PBS and challenged with isoproterenol to record emission of CFP and YFP.  
FRET was plotted as a ratio of emission of CFP over that of YFP.  Basal line subtraction was 
performed by Origin 8 and curve fitting was carried out by GraphPad.  
Statistical analysis  
    Curve-fitting and statistical analyses were performed using Prism software (GraphPad 
Software Inc., CA). 
3.4 Results 
Stimulation of the β2AR induces an agonist concentration-dependent receptor/Gi coupling in 
cardiac myocytes 
      By activation of the endogenous β2AR with Iso in β1AR-KO cardiac myocytes, we analyzed 
the endogenous β2AR-induced PKA activity through a FRET assay using the fluorescent 
biosensor AKAR 2.2. Activation of the β2ARwith 10 nM of Iso induced a transient peak in PKA 
activity, which returned to baseline levels within 5 minutes (Fig. 3.1A).  Pretreatment with PTX, 
which specifically inhibits Gi proteins by keeping it in inactive state, did not significantly change 
the β2AR-induced FRET response. However, a saturated concentration of 10 μM Iso induced 
more a sustained PKA FRET response, which was further enhanced with PTX pretreatment (Fig. 
3.1B). This data indicates that 10 μM of Iso, but not 10 nM of Iso, selectively induces β2AR/Gi 
coupling for PKA activity in cardiac myocytes. We then used a cardiac contraction rate assay to 
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examine the physiological consequences of this dose-dependent receptor/Gi protein coupling. We 
found that at 10 nM of Iso, the β2AR-induced increase in contraction rate was not PTX sensitive 
(Fig. 3.1C), whereas PTX significantly enhanced the increase in contraction rate induced by 10 
μM of Iso (Fig. 3.1D). These data again suggest that the β2ARcouples to Gi proteins only after 
stimulation with high concentrations of agonist. Consistent with this notion, the PKA-mediated 
phosphorylation of phospholamban, a PKA substrate that is critical for the βAR-induced cardiac 
contractile response, was enhanced by PTX only after stimulation with 10 μM of Iso (Fig. 3.1E). 
Previous reports have suggested that the PKA-mediated phosphorylation of the β2AR enhances 
the receptor coupling to  Gi protein (71, 144), and the GRK-dependent phosphorylation of the 
β2AR occurs only after stimulation with high concentrations of agonist (110), making the 
phosphorylation of β2AR a potential regulator of this dose-dependent Gi coupling in cardiac 
myocytes. 
Agonist stimulation induces a dose-dependent distinct PKA and GRK phosphorylation for β2AR 
internalization and signaling in cardiac myocytes 
     Analysis of the phosphorylation of β2AR in cardiac myocytes showed that the PKA-
dependent phosphorylation at serines 261/262 occurred at sub-nanomalor concentrations of Iso 
and displayed a dose-dependent increase (Fig. 3.2A-B). In contrast, the β2AR phosphorylation by 
GRK at serines 355/356 occurred only at 100 nM of Iso or at higher doses (Fig. 3.2A and 3.2C).  
After stimulation with a saturated 10 μM of Iso, the kinetics of the GRK- and PKA-mediated 
phosphorylation of the β2AR differed (Fig. 3.2D). The PKA-mediated phosphorylation showed a 
rapid increase, followed by a slow decrease, whereas the GRK-mediated phosphorylation was 
slower, but more sustained over time (Fig. 3.2E-F). It has been well-documented that the GRK-
mediated phosphorylation is involved in the endocytosis of β2AR in fibroblasts (85, 152), 
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prompting us to explore the role of β2AR phosphorylation in receptor internalization in cardiac 
myocytes. The activated β2ARs showed little punctuate staining upon stimulation with 10 nM of 
Iso in cardiac myocytes (Fig. 3A). However, stimulation with 10 μM of Iso induced a time-
dependent  clustering of β2ARs in the cells, similar to those reported previously (108), which is a 
characteristic of receptor internalization (Fig. 3.3A).  Moreover, removal of Iso after stimulation 
allowed the internalized receptor to return to the cell surface (Fig. 3.3A). These observations 
were further confirmed by quantification with a FLISA assay (Fig. 3.3B).  
     We then directly tested the role of phosphorylation in receptor internalization and signaling 
by using mutant β2ARs with the PKA- or GRK-phosphorylation sites replaced by alanines. The 
expression of both PKA mutant (PKAmut) and GRK mutant (GRKmut) were quantified and 
equalized through western blot and ligand binding (Fig. 3.4). Western blots of the mutant β2ARs 
also confirmed abolishment of the specific receptor phosphorylation events upon stimulation 
with 10 μM of Iso (Fig. 3.5). Immunostaining of the wild-type and PKAmut-β2ARs showed 
time-dependent internalization of the receptors after stimulation with 10 μM of Iso (Fig. 3.6A). 
However, the GRKmut-β2ARs failed to sufficiently internalize under Iso stimulation. Washout of 
Iso after 10 minutes of stimulation showed that the internalized receptors underwent recycling to 
the cell-surface (Fig. 3.6B). Quantification through the FLISA assay confirmed that the wild-
type and PKAmut-β2ARs, but not the GRKmut-β2ARs, were significantly internalized upon 10 
minutes of stimulation with 10 μM of Iso (Fig. 3.6C), supporting the necessary role of GRK 
phosphorylation in the internalization of the β2AR in cardiac myocytes. Together, the 
characterization of the mutant β2ARs revealed distinct actions of PKA and GRK on the receptor 
phosphorylation and trafficking in cardiac myocytes upon agonist stimulation, deeming the 
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phosphorylation deficient mutants suitable for closer examination on the effects on the receptor 
signaling in these cells.  
     By introducing either wild-type or mutant β2AR into β1β2AR-KO cardiac myocytes, we were 
able to examine the physiological effects of the phosphorylation of the β2AR upon receptor 
activation. Stimulation of the PKAmut-β2AR induced a stronger contraction rate increase over 
that of the wild-type (Fig. 3.7A). Stimulation of the GRKmut-β2AR showed a contraction rate 
increase similar to that of the wild-type, but this increase was much more sustained (Fig. 3.7A). 
Although the baseline contraction rates between the wild-type and mutant β2ARs were not 
significantly different (Fig. 3.7B), the maximal contraction rate increase induced by the 
PKAmut-β2ARwas significantly higher than that of wild-type (Fig. 3.7C). These data strongly 
support the conclusion that the phosphorylation of the β2AR has significant consequences in 
regulating myocyte contraction rate responses.  
PKA and GRK phosphorylation differentially regulate β2AR/Gi coupling in cardiac myocytes 
     By analyzing PKA activity in cardiac myocytes induced by these mutant β2ARs, we were able 
to observe the kinetics of upstream signaling, which leads to contraction induced by the receptors. 
Stimulation of the wild type, PKAmut-, or GRKmut-β2AR with 10 μM of Iso induced a stronger 
FRET increase in PKA activity than that of wild type β2AR, though the increase induced by the 
GRKmut- β2AR was less than those of the wild-type and PKAmut receptors (Fig. 3.8A). 
Inhibition of Gi proteins with PTX pretreatment significantly enhanced the PKA FRET increase 
induced by activation of the wild-type β2AR (Fig. 3.8B). However, the FRET response induced 
by the PKAmut- β2AR was insensitive to PTX (Fig. 3.8C), indicating that this receptor was 
unable to couple to Gi protein. Interestingly, the FRET response induced by the GRKmut-β2AR 
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was also PTX insensitive (Fig. 3.8D), indicating that the GRK-dependent phosphorylation was 
necessary for β2AR coupling to Gi proteins.  
     Extending the PKA FRET results into a contraction rate assay reinforced the physiological 
effects of this phosphorylation-dependent G protein-coupling phenomenon. While pretreatment 
with PTX significantly enhanced the wild type β2AR-induced increase in contraction rate upon 
stimulation with 10 μM of Iso (Fig. 3.9A and 3.9E), it did not significantly affect the PKAmut- 
β2AR-induced increase in contraction rate (Fig. 3.9B and 3.9E). Moreover, PTX did not enhance 
the GRKmut-β2AR-induced increase in contraction rate; instead, it lowered the contraction rate 
increase (Fig. 3.9C and 3.9E), which could be in part due to the enhanced baseline contraction 
rate by PTX treatment (Fig. 3.9D). These data suggest that both PKA and GRK phosphorylation 
are required for β2AR coupling to Gi protein, which thereafter affects myocyte contraction rate 
response.  
    We further employed a specific inhibitor of the Gi protein consisting of the C terminal portion 
of Gαi2 (GiCT, (153)) to probe receptor/Gi coupling by either wild type or mutant β2AR. We first 
determined that infection with GiCT virus at moi of 100 optimally inhibited receptor/Gi coupling 
and enhanced the β2AR-induced increase in contraction rate (Fig. 3.10A).  We then introduced 
GiCT along with wild-type or mutant β2AR into β1β2AR-KO cardiac myocytes. Overexpressing 
GiCT significantly enhanced the wild-type β2AR-induced increase in contraction rate (Fig. 3.10B 
and 3.10F), which was similar to that obtained with PTX treatment. However, GiCT did not 
affect the PKAmut- β2AR-induced increase in contraction rate (Fig. 3.10C and 3.10F). Similar to 
that of PTX treatment, inhibition of Gi protein with GiCT also reduced the GRKmut-β2AR-
induced increase in contraction rate (Fig. 3.10D and 3.10F). Overexpression of GiCT did not 
affect the baseline contraction rates (Fig. 3.10E). Together, we showed that inhibition of Gi with 
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GiCT significantly enhanced the maximal contraction rate induced by the wild-type, but not by 
the PKAmut- and GRKmut-β2ARs.   
3.5 Discussion 
    By measuring PKA activity and cardiac contraction rate increase, we show for the first time 
that β2AR activation of Gi proteins occurs selectively at high concentrations, but not at low 
concentrations of agonist. Moreover, we show that the receptor coupling to Gi proteins is 
differentially regulated by the PKA- and GRK-mediated phosphorylation of the activated β2ARs. 
At both low and high concentrations of agonist, the activated β2ARs undergo the PKA-mediated 
phosphorylation. In comparison, only high concentrations of agonist induce the GRK-mediated 
phosphorylation of the β2ARs for subsequent internalization, which is also necessary for 
sufficient receptor coupling to Gi proteins (108, 145). Our studies link together various 
components of the β2AR including receptor phosphorylation, receptor trafficking, and 
differential receptor/G protein coupling in cardiac cells, which may allow the activation of the 
β2AR signaling pathway to function as either a stimulatory or protective mechanism for cardiac 
cells under different levels of stress.  
     It has been well-documented that the PKA-mediated phosphorylation of β2AR enhances the 
receptor coupling affinity to Gi protein in a reconstituted system, and mutation of the PKA 
phosphorylation sites blocks receptor coupling to Gi in HEK293 fibroblasts (71, 144). In this 
study, we have further resolved the necessity of the PKA-dependent phosphorylation of β2AR in 
coupling to Gi proteins in cardiac myocytes. Activation of the murine β2AR by both low and high 
concentration of isoproterenol leads to phosphorylation of the receptor by PKA. At high 
concentrations of isoproterenol, the phosphorylation levels of the β2AR by PKA are further 
enhanced in comparison to those at low concentrations. This is probably due to dissociation of 
49 
 
phosphodiesterase 4D isoforms from the activated receptors (data not shown), which leads to 
higher local PKA activity for receptor phosphorylation. However, under stimulation with low 
concentrations of isoproterenol, the activated β2ARs do not couple to Gi, even if the PKA-
mediated phosphorylation occurs (Fig. 3.1 and 3.2). However, disruption of the PKA 
phosphorylation sites on the β2AR with mutagenesis blocks the receptor coupling to Gi (Fig. 3.8-
3.10). Together, these data indicate that PKA phosphorylation is necessary, but not sufficient, for 
the activated β2AR coupling to Gi in cardiac myocytes.  
    In contrast, the β2ARs undergo GRK-dependent phosphorylation only under stimulation with 
high concentrations of Iso (Fig. 3.2). Disruption of the GRK sites prolongs the Iso-induced 
myocyte contraction rate response (Fig. 3.7A), which is consistent with the notion that the 
phosphorylation of β2AR by GRK is required for rapid receptor desensitization (154). We do not 
observe obvious changes in the overall PKA activity induced by the GRKmut (Fig. 3.8A), 
probably because that the change is small and occurs in the local environment of the receptor, 
and thus is not sensed by PKA probes presented throughout the cytosol. However, similar to 
those of the PKAmut, the PKA FRET and contraction rate responses induced by the GRKmut-
β2AR do not show sensitivity to the inhibition of Gi protein (Fig. 3.8-3.10), indicating that the 
GRK-mediated phosphorylation is required for sufficient coupling to Gi. One possibility is that 
the GRK-phosphorylated receptors undergo internalization to promote the access of the receptor 
to Gi protein. Another possibility is that the GRK-mediated phosphorylation of the β2AR directly 
enhances the binding affinity of the receptor to Gi protein. However, evidence so far argues that 
the GRK phosphorylation-dependent receptor trafficking is more likely the key for sufficient 
receptor/Gi coupling. To support this notion, either blocking receptor internalization or 
disrupting receptor recycling through point-mutation on the PDZ motif of the β2AR blocks the 
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receptor/Gi coupling, which yields enhanced myocyte contraction responses  (145, 149). 
Moreover, Wang et al. have shown that direct inhibition of GRK2 activity blocks the receptor 
coupling to Gi proteins in myocytes (108). Furthermore, the GRK phosphorylation-dependent 
recruitment of arrestin/PDE4D complexes to the activated β2AR has been implicated in 
receptor/Gi coupling (155). These studies, together with our data, support the conclusion that the 
GRK-mediated phosphorylation of β2AR and subsequent receptor trafficking are critical for 
sufficient access of the receptor to Gi proteins. Consistent with this notion, a Gi specific inhibitor 
GiCT selectively blocks the receptor coupling to Gi without affecting the receptor coupling to Gs. 
These data suggest that the GiCT peptide did not compete against the unphosphorylated receptors 
in binding to Gs protein, but blocks the phosphorylated receptor in binding to Gi protein, which 
reinforces the idea that β2AR/Gi coupling is dependent on the agonist-induced phosphorylation 
of the receptor. Together, while the PKA-mediated phosphorylation is required for high affinity 
binding to Gi protein, the GRK-mediated phosphorylation is necessary for receptor trafficking 
that appears to control the accessibility of β2AR to Gi protein in cardiac myocytes.  
     Cardiac contraction in response to adrenergic stimulation is a tightly controlled process to 
ensure steady increases in cardiac output without overstimulation. Our observation of an agonist 
concentration-dependent switch of the activated β2AR coupling from Gs and Gi may be critical 
for such fine regulation. At low concentrations of catecholamines, the activated receptors will 
couple only to Gs for a stimulatory effect on cAMP/PKA activities for increasing cardiac 
contraction. However, in the presence of high concentrations of catecholamines, the activated 
β2ARs will switch from Gs to Gi to reduce cAMP/PKA activities in cardiac tissues, whereby 
preventing the overstimulation of cardiac contraction. The mechanism on how high 
concentrations of agonists can induce receptor phosphorylation by different kinases for 
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subsequent switch of G protein coupling is currently not known. Structural studies reveal that 
higher concentrations of agonists induce conformational changes distinct from those caused by 
low concentrations (151), which may enhance the receptor binding affinity to GRK. 
Alternatively, low concentrations may selectively activate the Gs protein-pre-coupled pool of 
receptors with high affinity binding, whereas higher concentrations of agonists activate both pre-
coupled and non-coupled pools of receptors. The latter pool of receptors may be involved in 
coupling to Gi proteins. The mechanism thus remains to be addressed. This protective 
mechanism by receptor/Gi coupling may be essential for preventing a high frequency of 
contractions, such as fibrillation during stress. In addition, β2AR/Gi coupling can play a 
protective role against the apoptotic effects induced by adrenergic/Gs stimulation (156-159). 
      More than a simple extension of the biochemical characterization of the β2AR, this study 
provides insightful information on the physiological effects of receptor phosphorylation by PKA 
and GRK. More importantly, it opens up questions about the nature of phosphorylation and its 
role in receptor desensitization, a concept that has been established in the last couple of decades. 
Undoubtedly, phosphorylation seems to play a role in diminishing the effects of receptor 
activation in cardiac myocytes, since abolishing those phosphorylation sites enhanced 
contraction rate over the wild-type upon stimulation (Fig. 3.7). However, we find that receptor 
phosphorylation appears to be critical in regulating contraction through coupling to different G 
proteins to protect cardiac cells from overwhelming agonist stimulation. Our study provides a 
clear step towards understanding the nature of receptor regulation by PKA- and GRK-mediated 
phosphorylation in a physiological context.  
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3.6 Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. Stimulation of the β2AR induces agonist dose-dependent coupling to Gi in 
cardiac   myocytes.   
 A-B) β1AR-knockout (KO) cardiac myocytes expressing the PKA biosensor AKAR2.2 were stimulated with 10 nM 
(A) or 10 μM (B) of Iso. Myocytes were treated with Gi protein inhibitor PTX for 2 hours before stimulation to 
examine the effect on PKA FRET activity induced by agonist. C-D) β1AR-KO cardiac myocytes were stimulated 
with 10 nM (C) or 10 μM (D) of Iso with and without PTX pretreatment, and the increases in contraction rate over 
baseline levels were measured as a function of time. E) β1AR-KO myocytes were stimulated with 10 nM or 10 μM 
of Iso with and without PTX treatment. The phosphorylation of phospholamban was detected and normalized 
against total phospholamban (N =4). **, p < 0.01 compared to the group without PTX treatment by two-way 
ANOVA. ***, p < 0.001 when compared to the group without PTX treatment by student’s t-test. 
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Figure 3.2. Stimulation of the β2AR induces agonist dose-dependent and dynamic receptor 
phosphorylation by PKA and GRK.  
 A) The β1β2AR-KO cardiac myocytes expressing flag-β2ARs were stimulated with different concentrations of Iso 
and blotted for phosphorylation by PKA (pS261/262) or GRK (pS355/356). The western blots in (A) were 
quantified and plotted as fold increases over baseline levels for the PKA-dependent phosphorylation B) and GRK-
dependent phosphorylation (C).  D) Myocytes expressing flag-β2ARs were stimulated with 10 μM of Iso for the 
indicated time to examine the PKA- and GRK-mediated phosphorylation. E and F) The western blots in (D) were 
quantified and plotted as fold increases over baseline levels. *, p < 0.05; **, p < 0.01when compared to the baseline 
levels by one-way ANOVA. 
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Figure 3.3.  Stimulation of the β2AR induces agonist dose-dependent internalization in 
cardiac myocytes.  
A) The β1β2AR-KO cardiac myocytes expressing flag-β2AR were stimulated with 10 nM or 10 μM of Iso for 10 min 
or 30 min, or 10 min Iso stimulation followed by drug removal for 30 min or 60 min. The flag-β2ARs were 
visualized through immunofluorescence imaging.  This data is representative of at least three experiments. B) The 
cell surface flag-β2ARs were quantified by FLISA in HEK293 cells after stimulation up to 10 or 30 min, or 10 min 
Iso stimulation followed by drug removal for 30 min or 60 min. Receptor levels were normalized against baseline 
levels (N = 5). **, p < 0.01 by student’s t-test. 
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Figure 3.4. Similar expression of β2AR, PKAmut-β2AR and GRKmut-β2AR. 
A) Cardiac myocytes were infected with adenoviruses expressing β2AR, PKAmut-β2AR and GRKmut- β2AR. After 
24 hours, equal amount of sample was loaded onto SDS-PAGE for western blot. M1 antibody was used for receptor 
level and tubulin was as internal control. B) Cells expressing all three receptors were broken by hypotonic buffer, 
and purified membrane was used for binding [3H] DHA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5. Mutation of PKA or GRK phosphorylation sites abolished the phosphorylation    
of mβ2AR upon agonist stimulation.  
Cardiac myocytes were infected with adenoviruses expressing human β2AR, mouse β2AR, PKAmut- β2AR and 
GRK-β2AR for 24 hours. Cells were treatment with or without 10 μM Isoproterenol for 5 minutes. Then cells were 
harvested for SDS-PAGE and western blots. 
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Figure 3.6.  Stimulation of wild-type and mutant β2ARs induces different receptor 
internalization and recycling.  
A) The flag-tagged β2AR, PKAmut-β2AR, and GRKmut-β2AR expressed in cardiac myocytes were stimulated with 
10 µM of Iso for different times before visualized by immunofluorescence imaging. B) The wild-type and mutant 
β2ARs were visualized for recycling after stimulation for 10 minutes followed by drug removal for the indicated 
times. This data is representative of at least three experiments. C) The cell surface wild-type and mutant β2ARs were 
quantified through FLISA after 10 min Iso stimulation, and recycling after drug removal for 30 and 60 minutes  in 
HEK293 cells (N = 3). Receptor levels were normalized against baseline levels. **, p < 0.01 by student’s t-test.  
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Figure 3.7. Activation of wild-type and mutant β2ARs induces distinct responses in 
contraction rates in cardiac myocytes.   
A) The β1β2AR-KO cardiac myocytes expressing β2AR, PKAmut-β2AR, or GRKmut-β2AR were stimulated with 10 
µM of Iso for contraction rate measurement. B) The baseline levels of contraction rates and C) the maximal 
increases in contraction rate after stimulation were plotted. ***, p < 0.001 when compared to the wild type β2AR by 
two-way ANOVA. *, p < 0.05 by student’s t-test.   
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Figure 3.8. Wild-type and mutant β2ARs differentially couple to Gi proteins to regulate 
agonist-induced PKA FRET responses.  
 A) The β1β2AR-KO cardiac myocytes expressing the PKA FRET biosensor AKAR2.2 together with the β2AR, 
PKAmut-β2AR, or GRKmut-β2AR were stimulated with 10 μM of Iso as indicated. The PKA FRET ratio was 
measured. B-D) Myocytes were also treated with PTX to access the receptor/ Gi coupling in regulating PKA FRET 
response after Iso stimulation. **, p < 0.01 and ***, p < 0.001 when compared to the wild type receptor by two-way 
ANOVA.  
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Figure 3.9.  Wild-type and mutant β2ARs differentially couple to Gi proteins to regulate 
agonist-induced contraction rate increases.  
A-C) The β1β2AR-KO cardiac myocytes expressing the β2AR, PKAmut-β2AR, or GRKmut-β2AR were stimulated 
with 10 μM of Iso in the presence or absence of PTX. The response in myocyte contraction rate was measured. D 
and E) The baseline levels of contraction rates and the maximal increases in contraction rates after stimulation in the 
presence or absence of PTX were plotted. ***, p < 0.001 when compared to the group without PTX treatment by 
two-way ANOVA. *, p < 0.05 when compared to the group without PTX treatment in student’s t-test.   
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Figure 3.10. GiCT inhibits β2AR/Gi coupling for myocyte contraction rate response upon 
agonist stimulation.  
A) The maximal responses in contraction rate induced by the β2AR were enhanced by expression of GiCT along 
with the wild type β2AR in β1β2AR-KO cardiac myocytes. B-D) The β1β2AR-KO cardiac myocytes expressing the 
β2AR, PKAmut-β2AR, or GRKmut-β2AR were stimulated with 10 μM of Iso in the presence or absence of GiCT. 
The response in myocyte contraction rate was measured. E and F) The baseline levels of contraction rates and the 
maximal increases in contraction rates after stimulation in the presence or absence of GiCT were plotted.   ** P < 
0.01 and ***, p < 0.001 when compared to the wild type receptor by two-way ANOVA. *, p < 0.05 when compared 
to the group without GiCT in student’s t-test.   
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CHAPTER 4 
The Effect of PKA and GRK Phosphorylation on β2AR Stability under Sustained Agonist 
Stimulation 
4.1 Abstract  
       Numerous studies have shown that post-translational modifications of β2AR (β2 
adrenoceptor) play an important role in modulation of the β2AR function. Mutation of either 
protein kinase A (PKA) or G-protein coupled receptor kinase (GRK) phosphorylation sites on 
β2AR reduces receptor recycling frequency, suggesting the critical role of these two 
modifications in maintenance of cell surface receptor level.  In the current study, we explored the 
effect of PKA and GRK phosphorylation on mouse β2AR stability in HEK293 cells under 
sustained agonist stimulation. Alanine substitution in either PKA phosphorylation sites (serines 
261, 262, 345 and 346) or GRK phosphorylation sites (serines 355, 356 and 358) on β2AR led to 
rapid receptor degradation than that of wild type β2AR. Immunofluorescence staining showed 
that both mutants had impaired ability of recycling back to cell surface. Instead, degradation of 
β2ARs occurred in lysosomes and could be prevented by biochemical inhibition of lysosome 
enzymes with chloroquine. Furthermore, by using antibodies against either extracellular or 
intracellular domains of β2AR, we found that lysosomes and proteasomes coordinated to degrade 
wild type β2AR: extracellular N-terminal domains of β2AR were degraded in lysosomes, whereas 
intracellular domains were cleared by proteasomes. Interestingly, majority of β2ARs with 
mutations on PKA sites were degraded in lysosomes, with minimal involvement of proteasomes. 
These data suggest the critical role of PKA and GRK phosphorylation of β2AR in maintenance of 
β2AR stability.  
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4.2 Introduction 
      β2AR plays a critical role in regulating physiological responses of animals to norepinephrine 
and epinephrine during stress (4, 108, 160).  Due to its protective role in cardiovascular 
physiology, β2AR structure has been extensively studied for designing high affinity agonists 
which may be potentially used for treatment of heart failure patients (160-162). Despite the great 
progress made in understanding the structure and activation of β2AR, little effort has been 
devoted to decipher how β2AR levels on the cell surface are regulated as it has been reported that 
a 30-fold increase of β2AR expression in transgenic mouse heart improves cardiac performance 
(163).  
      β2AR signaling is tightly regulated by post-translational modifications including 
glycosylation (69), palmitoylation (76), phosphorylation (70, 110, 164), and ubiquitination (82, 
117, 165). Most of these modifications occur at the C terminus of the receptor and play an 
important role in regulating receptor trafficking. β2AR activation by agonist binding leads to 
cAMP production through G protein coupling and adenylate cyclase activation. cAMP-
dependent PKA phosphorylates β2AR at serines 261 and 262 in the third intracellular loop,  and 
345 and 346 in the C terminus of the receptor (110). β2AR can be also phosphorylated by GRKs 
at the serine cluster (355, 356 and 358) of the C terminus which facilitates recruitment of 
scaffold protein β arrestin 2 for dual functions. β arrestin 2 binding interrupts receptor and Gs 
protein coupling, thus functionally desensitizing the receptor (85, 166, 167). β arrestin 2 
recruitment also initiates β2AR internalization through the clathrin-coated pit pathway mediated 
by dynamin (168). In addition, upon sustained agonist stimulation, β2AR undergoes 
ubiquitination of three lysine residues at the C terminus (lysines 348, 372 and 375) which are the 
primary sites of ubiquitination (80, 81). Two additional lysine residues in the intracellular loop 3 
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(lysine 263 and 270) are also involved in receptor ubiquitination (82).  
     Previous studies have suggested that β2AR trafficking is tightly regulated by a core amino 
acid sequence in the receptor. The four amino acids in the distal region of β2AR-DSLL is a 
substrate of GRK5 whose phosphorylation of the serine residue is important for binding between 
the receptor and EBP50 (ezrin-radixin-moesin (ERM)-binding phosphoprotein-50) (83). Loss of 
EBP50 binding reduces receptor recycling. Similarly, the ESKV sequence in the C terminus of 
the β1AR is important for receptor binding with SAP97/AKAP79/PKA complexes for recycling 
(169, 170). Meanwhile, mutation of the PKA phosphorylation site on β1AR abolishes receptor 
recycling (171). A recent study also shows that mutation of PKA phosphorylation sites (serines 
345 and 346) on β2AR reduces receptor recycling frequency (84). Mutation of all GRK 
phosphorylation sites on β2AR impairs receptor internalization and potential recycling (70, 85).  
     Intracellular vesicle sorting proteins also regulate β2AR trafficking fate.  After receptor 
internalization via the clathrin-coated pit pathway, the β2AR-ligand complex is sorted to 
peripheral tubulovesicular sorting endosomes where ligand is dissociated from the complex due 
to the acidic pH.  β2AR may rapidly recycle back to the cell surface through the recycling 
endosomes mediated by Rab4, a GTPase of the Rab families regulating vesicle trafficking (84, 
87, 88). β2AR may also recycle slowly back to the cell surface through recycling endosomes, 
which is mediated by Rab11 GTPase (89, 90). Studies have shown that these two recycling 
endosomes are quite different (91, 92, 172). Alternatively, β2ARs are sorted to lysosomes or 
proteasomes for degradation, thus terminating receptor signaling (81, 82, 93). Two key proteins 
have been identified in sorting internalized β2AR from early endosomes to lysosomes: GASP (G 
protein coupled receptor sorting protein) and Hrs (hepatocyte growth factor-regulated tyrosine 
kinase substrate). GASP has been shown to bind to the C terminus of several GPCRs and 
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dominant-negative inhibition of GASP blocks the lysosome sorting and degradation of the 
receptors, including β2AR (94-96). Hrs is a mammalian homologue of VPS27 (vacuolar protein-
sorting) protein in the yeast. Hrs associates with endosome membranes and binds to 
ubiquitinated or non-ubiquitinated cargoes and sorts them for recycling as well as for 
degradation in lysosomes (97, 98). 
      Increase or maintenance of β2AR levels on the plasma membrane provides a compensatory 
mechanism to protect the heart under chronic stress conditions. To maintain that constant level, 
cells may utilize various mechanisms to prevent β2ARs from degradation. Studies have shown 
that under sustained stimulation, β2ARs undergo minimum degradation in HEK293 cells with a 
half-life more than 10 hours. This minimum β2AR degradation is mediated by a ubiquitination-
dependent pathway by Mdm2 and Nedd4 E3 ligases (93, 116).  In addition, there is a controversy 
about whether ubiquitination-dependent β2AR degradation is in lysosomes or in proteasomes. 
Currently, there is no clear answer to that question.  Studies on the degradation of other 
membrane receptors indicate that receptors may be degraded by both lysosomes and proteasomes: 
extracellular domains are degraded by lysosomes and intracellular domains are degraded by 
proteasomes respectively (106, 107). In that scenario, we set out to explore whether it is true that 
extracellular and intracellular domains β2ARs are degraded differently. Moreover, we want to 
understand whether PKA and GRK phosphorylation of β2AR influence receptor stability. As 
both PKA and GRK phosphorylations are implicated in efficient recycling of β2AR, we 
hypothesize that loss of either phosphorylation promotes β2AR degradation. Indeed, we find that 
alanine substitution in either PKA or GRK phosphorylation sites leads to rapid receptor 
degradation in lysosomes. More interestingly, we find for the first time that both lysosomes and 
proteasomes coordinate to degrade β2ARs: extracellular domains of the receptor are degraded in 
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lysosomes, and intracellular domains are degraded in proteasomes.  Upon loss of PKA 
phosphorylation sites, the receptor undergoes degradation in lysosomes with minimal 
involvement of proteasomes. These data reveal a novel mechanism that PKA and GRK 
phosphorylation dictate the receptor degradation processes, and prevents the lysosome-dependent 
default degradation of the receptor.  
4.3 Materials and Methods 
Reagents 
     (-) Isoproterenol (+)-bitartrate salt (I2760), Chloroquine diphosphate salt (C6628), MG132 
(C2211), Streptavidin-agarose (S1638), anti-Flag M2 affinity Gel (A2250), 2-
bromohexadecanoic acid (21604 ) and N-thylmaleimide (E3876) are all from Sigma. EZ-Link 
Sulfo-NHS-LC-LC-biotin (21338) and streptavidin-HRP (21130) are from Thermo Scientific.  
Lipofactamine 2000 (11668-019) and natural mouse laminin (23017015) are from Invitrogen. 
G418 sulfate (61-234-RG) is from Mediatech Inc. 
Site-directed mutagenesis  
     PKAmut-β2AR or GRKmut-β2AR was created by substitution of either four PKA 
phosphorylation sites (serines 261, 262, 345 and 346) or GRK phosphorylation sites (serines 355, 
356 and 358) for alanines using site-directed mutagenesis method. All mutations were verified 
by DNA sequencing.  
Stable cell line establishment  
HEK293 cells that stably express mouse β2ARs were created by transfection of the cells with 
pCDNA-flag-mβ2AR and mutant β2ARs with Lipofactamine 2000. After 24 hours, cells were 
maintained in DMEM supplied with 0.7g/L G418 sulfate to select stable cell lines for about one 
week.  Comparison of the receptor expression level between wild type β2AR and mutant β2ARs 
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was carried out by Western blot using the same amount of cells. Gamma tubulin was used as an 
internal control.  
Receptor degradation assay    
      Cells were cultured to 100% confluence in six centimeter dishes and washed once with room 
temperature phosphate buffered saline (PBS) before beginning the experiment. Cell surface 
protein biotinylation was performed by incubation of the cells with 300 μg biotin dissolved in 
PBS for 30 minutes at 4 °C. After biotinylation, cells were washed once with 50 mM glycine to 
stop biotinylation and refed with serum free DMEM for isoproterenol stimulation for 10 and 20 
hours. Chloroquine was added at final concentration of 150 μM and MG132 was provided at 
final concentration of 12 μM. Cells were harvested into 700 μl lysis buffer (20 mM HEPES, 1% 
NP40, 150 mM NaCl, 1 mM EDTA, 1 mM Benzamidine, 1 mM PMSF, 1 mM NaF, 1 mM 
Na3VO4),  and lysed for 30 minutes at 4°C before centrifugation for 10 minutes at 16100 x g to 
collect the supernatant. Streptavidin-agarose or anti-flag M2 affinity gel was incubated with the 
supernatant for 2 hours at 4°C and washed three times with the same lysis buffer. Proteins were 
eluted into 2x SDS-sample buffer and subjected to SDS-PAGE for blot with anti-flag antibody 
(Sigma, MO), anti-β2AR C-terminal antibody (β2AR-M-20, Santa Cruz biotechnology, CA) or 
streptavidin-HRP.  
Receptor trafficking  
Cells stably expressing mβ2AR, PKAmut-β2AR and GRKmut-β2AR were grown on glass 
microscope coverslips coated with laminin and maintained in DMEM supplied with 10% fetal 
bovine serum. Cells were serum starved for 30 minutes and stimulated with 10 μM Iso for 30 
minutes for receptor internalization. For receptor recycling, cells were stimulated with 10 μM Iso 
for 30 minutes followed by rinsing three times with PBS and maintained in serum free DMEM 
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for recycling for 1 hour and 4 hours. Cells were immediately fixed with 4% formaldehyde for 15 
minutes at room temperature and permeabilized with 0.2% NP-40. To stain β2ARs, cells were 
incubated with anti-flag M1 antibody and Alex 488 conjugated goat-anti-mouse secondary 
antibody. Images were taken by a CCD camera attached to the Zeiss microscope controlled by 
MetaMorph software.   
4.4 Results 
Mutation of either PKA or GRK phosphorylation sites leads to rapid β2AR degradation at both 
basal and stimulation conditions 
     We successfully established HEK293 stable cell lines expressing wild type β2AR, PKAmut-
β2AR and GRKmut-β2AR using G418 resistance as a selection marker. Mutation of either PKA 
or GRK phosphorylation sites on β2AR did not change receptor expression level or agonist 
binding affinity by transient expression of the β2ARs in neonatal myocytes (70). However, we 
observed low expression level of GRKmut-β2AR in HEK293 stable cell line in our study, 
possibly due to the rapid degradation of the mutant observed later. To examine the effect of loss 
of either PKA or GRK phosphorylation on β2AR stability, cell surface proteins were biotinylated 
in the presence or absence of 10 μM Iso stimulation for 10 and 20 hours. The remaining 
biotinylated receptors were then examined by two methods. In the first method, the supernatant 
was incubated with anti-flag M2 affinity gel to immunoprecipitate all flag-β2ARs. The remaining 
biotinylated flag-β2ARs were detected by streptavidin-HRP (Fig. 4.1). In the other method, the 
supernatant was incubated with streptavidin-agarose to pull down all biotinylated membrane 
proteins and the remaining biotinylated receptors over time were detected by anti-flag antibody 
(Fig. 4.2). By utilizing both methods, we found that wild type β2AR was substantially resistant to 
degradation in HEK293 cells, consistent with a previous study that the half life of β2AR is 
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greater than 10 hours (83). Both mutant β2ARs were rapidly degraded under basal and 
stimulation conditions (Fig. 4.1 and Fig. 4.2). These data indicate that both PKA and GRK 
phosphorylation of β2AR stabilize β2AR.  
PKAmut-β2AR and GRKmut-β2AR are accumulated inside cells instead of recycling back to cells 
surface 
    PKA and GRK phosphorylation of β2AR plays different roles in receptor signaling regulation. 
PKA phosphorylation has been shown to regulate receptor/Gi coupling (70, 71). Mutation of four 
PKA phosphorylation sites to alanines leads to reduced recycling frequency (84). GRK 
phosphorylation of β2AR leads to recruitment of scaffold protein β arrestin 2 for receptor 
internalization through clathrin-coated pit pathway.  It is reasonable to hypothesize that the rapid 
degradation of mutant receptors is due to abnormal receptor trafficking. Therefore, we examined 
the trafficking properties of three β2ARs after Iso stimulation or stimulation followed by drug 
washout for recycling. As shown in Fig. 4.3A, upon stimulation with 10 μM Iso, all three β2ARs 
were internalized inside cells as indicated by punctate staining in the cytosol although we 
observed slow internalization rate of GRKmut-β2AR, possibly due to the abolished recruitment 
of β arrestin 2. Upon Iso removal, wild type β2AR recycled back to the cell surface efficiently, 
consistent with less receptor degradation shown in Fig. 4.1-4.2. However, both PKAmut-β2AR 
and GRKmut-β2AR were accumulated inside cells indicating that they lost the ability of 
recycling back to the cell surface. These data indicate that loss of recycling back to cell surface 
may contribute to rapid degradation of PKAmut-β2AR and GRKmut-β2AR. 
     Then we examined the subcellular localization of PKAmut-β2AR and GRKmut-β2AR upon 
sustained agonist stimulation. Other studies have shown that efficient recycling of β2AR requires 
the function of both Rab4 and Rab11, small GTPases in vesicle trafficking (84, 90). Rab11 and 
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binding partners are also involved in β1AR recycling (173).  Therefore, we hypothesized that 
β2AR mutants may not traffic to Rab4 or Rab11 mediated recycling endosomes, which may help 
explain the rapid degradation of the receptors. As shown in Fig 4.3B, expression of dominant 
negative Rab4 (S27N), Rab11 (S25N) or together in HEK293 stable cell lines did not prevent the 
degradation of either of two receptors. It is possible that under sustained agonist stimulation, 
blockade of receptor degradation by overexpression of dominant negative Rabs is not sensitive 
enough for detection of differences as most of studies use Rabs for β2AR imaging.  
β2ARs are degraded in lysosomes and proteasomes 
      We then examined whether β2ARs are degraded in lysosomes and proteasomes. As shown in 
Fig 4.4 A-C, upon treatment of the cells with chloroquine to inhibit lysosome enzymes (174), 
degradation of all three β2ARs was partially prevented indicating that β2ARs were targeted to 
lysosomes for degradation. Inhibition of proteasome activities by MG132, which is a membrane-
permeable short peptide commonly used to prevent proteasome-mediated protein degradation, 
did not restore the protein level of all three receptors. Furthermore, this was not due to 
insufficient concentration of MG132 applied. As the concentration of MG132 was increased to 
20 μM at which cells started to die due to the toxicity of MG132, the degradation of wild type 
β2ARs was still not prevented as detected by the receptor level using antibody against flag-tag 
(Fig. 4.4D). 
     The traditional view of membrane protein degradation is through an early endosomes-late 
endosomes-lysosomes pathway. Alternatively, proteins can also be degraded in proteasomes 
mediated by ubiquitin. Currently, there is no clear explanation describing the degradation of 
β2AR. A very interesting hypothesis regarding β2AR degradation proposed several years ago was 
that extracellular and intracellular domains are differentially degraded by lysosomes and 
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proteasomes. To further test this concept, we repeated the β2AR degradation inhibition by 
chloroquine and MG132 treatment. We determined the β2AR level with both anti-flag and anti-C 
terminus antibodies.  Again, degradation of β2AR and PKAmut-β2AR were prevented by 
chloroquine and not by MG132 treatment when we examined the receptor level by anti-flag 
antibody (Fig. 4.5 A-B first panel). When using anti-C terminus antibody to detect β2ARs, we 
found different receptor fates: degradation of wild type β2AR was prevented by MG132 but not 
by chloroquine treatment. Degradation of PKAmut-β2AR was still mainly mediated by 
lysosomes, and to a lesser extent by proteasome, no matter which antibody was used to detect 
receptor level. 
4.5 Discussion 
β2AR is a prototypical GPCR that is extensively studied due to its cardiac protective effect. It 
has been shown that a 30-fold increase of β2AR expression improves cardiac performance (163). 
This indicates that β2AR levels on the cell surface are critical for myocyte response to 
physiological stimulation. In this current study, we explore the effect of two post-translational 
modifications on regulation of β2AR stability. We show that loss of either PKA or GRK 
phosphorylation leads to rapid β2AR degradation in lysosomes under both basal and stimulation 
conditions.  
      The rapid degradation of β2ARs was not due to mRNA instability (175), indicating that the 
normal transcription-translation machinery of β2AR was still maintained under sustained agonist 
stimulation. Also, it might not be due to receptor instability caused by mutation of the 
phosphorylation sites. Mutation of four PKA phosphorylation sites to aspartic acids, which 
mimics the phosphorylation state of the receptor, also led to rapid degradation of the receptor in 
our study (data not shown). It suggests that aspartic acid substitution of serine residues may not 
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behave the way as the native phosphorylation status of the receptor, and thus we still can not rule 
out the possibility that the rapid degradation of the mutant receptors is due to the instability 
caused by the mutations. To further test that, PKA activity inhibitor H89 may be used to examine 
whether the degradation of wild type β2ARs can be blocked or reduced by inhibition of PKA 
activity. 
      The molecular mechanisms underlying the rapid degradation of PKAmut-β2AR and 
GRKmut-β2AR might be different. PKA and GRK phosphorylation play different roles in 
regulation of β2AR signaling. Mutation of four serine PKA phosphorylation sites does not impair 
the β2AR internalization but leads to less β2AR recycling frequency (84). In our preliminary 
studies, we demonstrate that Iso increases the ubiquitination of PKAmut-β2AR which is 
subsequently degraded in lysosomes, consistent with ubiquitination-lysosome mediated EGFR 
degradation (176). It has been shown that PKA phosphorylation of RhoA and β-catenin protects 
them from ubiquitination mediated degradation (177, 178), further supporting the role of PKA 
phosphorylation in maintaining β2AR stability.  
      GRK mediated phosphorylation of three serines at the C-terminus of β2AR facilitates the  
recruitment of β arrestin 2 for receptor internalization as well as ubiquitination (116). Loss of 
GRK phosphorylation of β2AR is expected to abolish the ubiquitination of β2AR upon agonist 
stimulation, suggesting that another molecular mechanism rather than ubiquitination regulates 
rapid degradation of GRKmut-β2AR. It will be interesting to examine whether GRKmut-β2AR 
has increased binding of G protein sorting proteins (GASP), which mediates the receptor 
degradation in lysosomes. 
     The most remarkable discovery in this study is the dual β2AR degradation by lysosomes and 
proteasomes (Fig. 4.5). We demonstrate that the extracellular domains of β2ARs are degraded in 
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lysosomes and the intracellular domains are degraded in proteasomes. To further prove the 
differential β2AR degradation by proteasomes and lysosomes, we may replace the N terminus of 
β2AR with that of β1AR and study the degradation of this chimeric receptor. Since β1AR is 
resistant to degradation, N terminus substitution of β2AR may lead to reduced degradation in 
lysosomes but not that in proteasomes. Similarly, replacement of the C terminus of β2AR with 
that of β1AR might lead to receptor degradation in lysosomes but not in proteasomes. In addition, 
the molecular mechanism underlying the differential degradation is not clear yet. Several studies 
suggest that ubiquitination of EGFR targets degradation of cytosolic/ intracellular domains in 
proteasomes, then the intact “de-ubiquitinated EGFR” is subsequently transferred to lysosomes 
for degradation (176). Degradation of erythropoietin receptor, the major regulator of red blood 
cell production in kidney, also involves both proteasomes and lysosomes (107). In terms of β2AR 
degradation, agonist stimulation may lead to mild ubiquitination increase of wild type β2AR, 
which may target intracellular domains of receptor for degradation in proteasomes, and then 
extracellular domains of β2AR are released and transferred to lysosomes for further degradation. 
An alternative hypothesis is that instead of sequential degradation by proteasomes and lysosomes, 
β2AR degradation may occur at the same time: the extracellular domains are degraded in the 
lumen of lysosomes and intracellular domains containing ubiquitin are degraded in proteasomes. 
For PKAmut-β2ARs, upon agonist stimulation, they may be transferred to multivesicular bodies 
and are then released into the lumen of lysosomes for degradation with minimal involvement of 
proteasomes.  However, the mechanism underlying our observations remains to be addressed. 
    Together, we provide new insight into understanding how post-translational modifications 
regulate β2AR signaling under sustained agonist stimulation. Agonist stimulation of β2AR leads 
to both PKA and GRK phosphorylation of the receptor, which coordinately protects the receptor 
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from degradation, thus maintaining cell surface β2AR levels. We also demonstrate for the first 
time that both lysosomes and proteasomes are involved to degrade different regions of the β2AR 
for a complete degradation.  
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4.6 Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1. Mutation of either PKA or GRK phosphorylation sites on β2AR leads to rapid 
receptor degradation under both basal and stimulatory conditions.  
HEK293 cells stably expressing β2AR, PKAmut-β2AR and GRKmut-β2AR (A and B) were labeled with biotin (300 
μg /dish) for 30 minutes at 4 °C, and then treated with 50 mM glycine to stop the biotinylation. Cells were 
stimulated with or without 10 μM Iso for indicated time. Immunoprecipitation was carried out using M2 beads. 
Quantification of the receptor degradation was based on five different experiments. *, p<0.05,   **, p<0.01 by 
student’s t-test.  
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Figure 4.2. Mutation of either PKA or GRK phosphorylation sites on β2AR leads to rapid 
receptor degradation under both basal and stimulatory conditions. 
HEK293 cells stably expressing β2AR, PKAmut-β2AR and GRKmut-β2AR were labeled with biotin (300 μg/ml) for 
30 mins at 4 °C, and then treated with 50 mM glycine to stop biotinylation. Cells were stimulated with or without 
Iso for indicated time. Biotinylated membrane proteins were pulled down with streptavidin-agarose and detected by 
anti-flag antibody. Quantification of the receptor degradation was based on four different experiments. *, p<0.05,   
**, p<0.01 by student’s t-test.  
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Figure  4.3. PKAmut-β2AR and GRKmut-β2AR are not efficiently recycled back to cell 
surface in HEK293 cells.  
A) HEK293 cells stably expressing β2AR, PKAmut-β2AR and GRKmut-β2AR were stimulated with 10 μM Iso for 
30 minute for internalization or followed by Iso washout for recycling for 1 hour and 4 hours. Cells were fixed, 
permeabilized and stained with anti-flag antibody which was visualized by Alex 488-conjugated secondary antibody.  
B) Cells stably expressing β2AR or PKAmut-β2AR were co-transfected with dominant-negative Rab4, Rab11 or 
together  to study the effect on receptor degradation.  
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Figure 4.4.  β2ARs are degraded in lysosomes and to a lesser extent in proteasomes.  
A-C) HEK293 stable cell lines expressing wild type and mutant β2ARs were biotinylated and treated with 150 μM 
chloroquine or 12 μM MG132 to block the degradation. Membrane receptors were detected by anti-flag antibody. D) 
Cells expressing wild type β2AR were incubated with increasing doses of MG132 to study receptor fate over time. 
Protein samples from pulling down were detected by anti-flag antibody.  
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Figure  4.5.  Receptors are degraded in both lysosomes and proteasomes. 
HEK293 cells stably expressing wild type β2AR or PKAmut-β2AR were biotinylated to study receptor fate over time. 
Proteins in the pull down were detected by both anti-flag and anti-β2AR C-terminus antibody.  
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CHAPTER 5 
 
Summary 
 
     The seven transmembrane receptor β2AR plays an important role in regulating physiological 
responses of animals to neurotransmitters and hormones (179-184).  In the present study, we 
revealed the effects of palmitoylation, PKA and GRK phosphorylation on β2AR signaling in 
neonatal cardiac myocytes and HEK293 cells. Our study provides new insight into the 
understanding of β2AR signaling regulation by post-translational modifications.  
      First, we demonstrated that palmitoylation is not required for β2AR targeting to caveolae on 
the plasma membrane, consistent with the dynamic property of β2AR palmitoylation. Instead, 
palmitoylation and GRK phosphorylation mediate the association of β2AR with β arrestin 2-
PDE4D complexes to control cAMP/PKA activity in cardiac myocytes. We show for the first 
time that palmitoylation is involved in recruitment of arrestin-PDE4D complexes, thus providing 
a new mechanism for cAMP-PKA activity modulation. It will be of great interest to study how 
overexpression of the palmitoylation mutant β2AR in transgenic mice alters the function of the 
heart.      
Second, we showed that β2AR coupling to Gi is agonist concentration dependent and is 
controlled by both PKA and GRK phosphorylation of the receptor. At low concentrations of 
agonist, β2AR only couples to Gs to initiate cAMP/PKA activity for normal heart function. PKA 
phosphorylation occurs at low agonist concentrations, which is not enough to trigger receptor/Gi 
coupling. At high concentration of agonist stimulation, both PKA and GRK phosphorylation 
occur, and the receptors undergo internalization for receptor access to Gi. This finding has great 
correlation with physiological circumstances in which only at high agonist concentrations, β2AR 
couples to Gi to prevent cells from overstimulation. While previous studies indicate that PKA 
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phosphorylation of β2AR enhances the coupling affinity to Gi proteins (71), our data indicate that 
GRK phosphorylation-dependent receptor translocation is required to increase the accessibility 
of the receptor to initiate Gi coupling, presumably via receptor internalization and rapid recycling. 
In addition, GRK2 activation needs PKA phosphorylation of GRK2, which may underline 
another layer of cross regulation of receptor signaling by phosphorylation of the β2AR dependent 
on these two kinases (185). Besides cardiac tissue, it has been reported that at high agonist 
concentrations, both PKA and GRK phosphorylation are required to control smooth muscle 
relaxation in the lung (186).        
Thirdly, we explored the role of PKA and GRK phosphorylation on β2AR stability under 
sustained agonist stimulation. We show that loss of either phosphorylation sites on β2AR leads to 
rapid degradation in lysosomes and proteasomes, suggesting that both phosphorylations are 
required for β2AR stability. Moreover, we demonstrate new mechanisms for β2AR degradation: 
the extracellular domains of the receptor are degraded by lysosomes and the intracellular 
domains of the receptor are cleared by proteasomes.  
       Together, our study contributes to understanding of β2AR signaling regulation by post-
translational modifications in physiologically relevant cardiac myocytes. At low concentrations 
of agonist, activation of β2AR leads to an increase of the cAMP-PKA activity to trigger 
cardiomyocyte contraction without receptor/Gi coupling. At high levels of stress, β2AR utilizes 
multiple mechanisms to tightly regulate the cAMP/PKA signaling amplitude: β2AR couples to Gi 
to terminate signaling; increased palmitoylation level of β2AR facilitates the recruitment of β 
arrestin 2/PDE4D complexes to degrade cAMP.  Sustained agonist stimulation leads to increased 
PKA phosphorylation to reduce β2AR degradation in lysosomes and proteasomes, while GRK 
phosphorylation increases the recruitment of arrestin to the receptor, which may facilitate 
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recycling of the receptor by preventing receptor from sorting into lysosomes/ proteasomes for 
degradation.  
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